‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports

Laura Orsolini[*1,2,3], John M. Corkery[1], Stefania Chiappini[1], Amira Guirguis[1], Alessandro Vento[4,5,6,7], Domenico De Berardis[3,8,9], Duccio Papanti[1], and Fabrizio Schifano[1]

[1] Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK.
[2] Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy.
[3] Polyedra, Teramo, Italy.
[4] NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy
[5] School of psychology - G. Marconi Telematic University, Rome, Italy
[6] Addictions Observatory (ODDPSS), Rome, Italy
[7] Mental Health Department - ASL Roma 2, Rome, Italy
[8] Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, Italy.
[9] NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 Teramo, Italy.

Corresponding author:
Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: laura.orsolini@hotmail.it. Tel.: (+39) 392 3244643.

Conflicts of Interest

The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgements

This paper was supported in part by grants of the European Commission (Drug Prevention and Information Programme 2014-16; contract no. JUST/2013/DPIP/AG/4823; *EU-MADNESS project*). Further financial support was provided by the EU Commission-targeted call on cross border law enforcement cooperation in the field of drug trafficking - DG Justice/DG Migrations and Home Affairs (JUST/2013/ISEC/DRUGS/AG/6429) *Project EPS/NPS* (Enhancing Police Skills concerning Novel Psychoactive Substances; NPS).

'New/Designer Benzodiazepines': an analysis of the literature and psychonauts' trip reports

Abstract (current word count 253)

***Background*. NPS belonging to the benzodiazepine (BZD) class, e.g., '*legal/designer BZDs*'/'*research chemicals*', have recently emerged on the drug (mainly online/virtual) market.**

***Objective*. Whilst certain NPS belonging to the BZD class possess pharmacological profiles similar to controlled pharmaceutical BZDs, clinical and pharmacological profiles of current emerging BZDs are still not well-described. Therefore, there is a need to increase clinicians'/public health knowledge/awareness, to incentive harm reduction strategies.**

***Method*. A comprehensive overview was carried out by using the EMCDDA/EDND database regularly monitored by our research team, by specifically looking at the 'new BZDs' so far notified. Furthermore, given the limitation of peer-reviewed data published so far, a nonparticipant multilingual qualitative netnographic study was conducted to obtain further clinical/pharmacological/toxicological data, including psychonauts' online trip reports.**

***Results*. First designer BZDs appeared as NPS around 2007. So far, 29 designer BZDs have been notified to the EMCDDA, being some of them extremely powerful, also at lower dosages. They are sold as tablets/powder/pellets/capsules/blotters/liquids, at very affordable prices, and variably administered. Some are also sold on the illicit drugmarket as counterfeit forms of traditional BZDs or as either adulterants or diluents in heroin or other synthetic opioids/cannabinoids. Nowadays, there is no guarantee of the quality of designer BZDs composition/purification and, hence, most NPS consumers may be inadvertently exposed to unsafe and harmful compounds.**

***Conclusions*. Given the limited information on their pharmacology/toxicity, variations in dosage, onset of effects, combination of substances, potency, and general patient or individual variability, the concomitant use of these substances with other drugs entails several and unpredictable risks.**

Keywords: New benzodiazepines; NPS; novel psychoactive substances; benzodiazepines; designer benzodiazepines; synthetic benzodiazepines.

1. Introduction

Benzodiazepines (BZDs) acts as positive allosteric modulators on the gamma-aminobutyric acid $(GABA)_A$ receptor [1]. GABA represents the main inhibitor neurotransmitter in the brain and plays an important role in modulating the activity of many neurons, including those in the amygdala and prefrontal cortex [1]. The $GABA_A$ receptor is a ligand-gated chloride-selective ion channel build-up of five subunits: two α, two ß (the binding site for endogenous neurotransmitter) and one γ. BZDs bind to the pocket created by α and γ subunits and induce a conformational change in the $GABA_A$ receptor. This alteration, in turns, induces a conformational change in the $GABA_A$ receptor such as to increase the apparent affinity for channel gating by GABA at both agonist sites. As a result, maximal currents elicited by GABA remain unaffected, and the GABA concentration channel opening curve is shifted to lower GABA concentrations' chloride channel that hyperpolarizes the cell and accounts for GABA's inhibitory effect throughout the central nervous system [1]. These complex pharmacological activities explain the different clinical effects (i.e., anxiolytic, hypnotic, anticonvulsant, amnestic, and muscle relaxant) of BZDs. The pharmacological activity of BZDs is determined by the type of $GABA_A$ receptor α subunit to which they bind. Thus, the sedative, anterograde amnesic and anticonvulsant actions, as well as the addictive potential of these drugs, require the presence of α_1-containing $GABA_A$ receptors, while the anxiolytic effects are mediated by $GABA_A$ receptors containing α_2 subunits, and the myorelaxant actions by $GABA_A$ receptors containing α_2, α_3, and α_5 subunits [2].

Overall, BZDs are generally classified according to their pharmacokinetic characteristics, i.e. a) plasma half-life ($t_{½}$); and, b) hepatic metabolism [1; 3] (*Table 1*). Plasma half-life ($t_{½}$) represents the hours required for the concentration of the drug in the body to be reduced to half of the maximum concentration. In detail, $t_{½\alpha}$ represents the '*phase distribution*' from the vascular system to the tissues; whilst $t_{½\beta}$ indicates the '*elimination phase*' and represents, hence, an index of the metabolism and excretion of BZDs. This phase varies significantly

among different BZDs (from 2-3 hours up to more than 100 hours) and is relevant for the accumulation of some BZDs in tissues after long-term use (see *Table 1* for more details). Furthermore, BZDs may be classified according to their chemical structure and designer BZDs are mainly classified as either 1,4-benzodiazepines (a structure shared by most 'traditional' BZDs), triazolo-BZDs, or thienotriazolodiazepines (*Table 1*) [4]. BZD metabolism mainly occurs in the liver, primarily by oxidative metabolism mediated by the cytochrome P450 (CYP450) family, i.e. CYP3A4, CYP3A5, CYP2C19, CYP2C18, CYP2C9 and CYP2B6 [5]. Tolerance and dependence may occur shortly after consumption has started, which requires dose increase and may trigger drug-seeking behaviours [1; 3]. Acute intoxication may cause respiratory and central nervous system depression, even though is rarely lethal if the BDZ is taken alone [6]. However, BZDs are usually consumed in combination with other depressant drugs/substances (i.e., opioids, antidepressants, etc.), as commonly documented amongst opioid consumers in order to enhance their euphoric effects, alleviate withdrawal or abstinence symptoms, or temper highs induced by psychostimulants or synergistically enhance alcohol effect [1; 3].

As a relatively new phenomenon, novel psychoactive substances (NPS) belonging to the BZD class have emerged on the drug (mainly online/virtual) market, and are being sold under street names such as '*legal benzodiazepines*', '*designer benzodiazepines'* or '*research chemicals*'. This group of drugs includes substances that were tested but not approved as medicines in the pharmaceutical industry or that have been manufactured by modifying the core structure of existing pharmaceutical BZDs [7-9]. Whilst certain NPS belonging to the BZD class possess pharmacological profiles similar to the 'controlled' pharmaceutical BZDs, profiles of most of the current designer/NPS BZDs are not completely well-described, hence, their safety, toxicological and clinical profile are still unknown, posing serious health risks to consumers [9-10]. Furthermore, the risk of polydrug use involving BZDs and opioids (both traditional and synthetic ones) are furtherly intensified by NPS belonging to these new/designer BZDs [10]. Given the limited information on the pharmacology and toxicity of these substances, variations in the dosage, onset of effects, combinations with other substances, potency, and general patient or individual variability, the concomitant use of these substances with other drugs entails several and unpredictable risks, particularly amongst high-risk opioid users [11]. Interestingly, it has been observed both over the long-term and in the last few years that a diverse range of NPS, including synthetic opioids and BZDs, are appearing [10]. In fact, by the end of 2018, **EMCDDA monitored** more than 730 NPS, of which 55 were reported for the first time in Europe in 2018, of which around 5% belonging to the BZD class [10]. So far, 29 NPS belonging to the BZD class have been reported by Member States to the UNODC Early Warning Advisory (EWA), of which 23 were firstly detected in Europe during the last 5 years [10]. In 2008, phenazepam was the first new BZD to be reported to the EWA. In 2011, Germany, Norway and the United Kingdom were the first countries to report the emergence of another designer BZD, etizolam. In the following years (2012-2013), a relative stable number of BZDs were reported to the EMCDDA; with an increased number in 2014-2016, a reduction in 2017 and a further increase in 2018 [10].

Some new BZDs were sold as tablets, capsules or powders under their own names, marketed as 'legal' versions of authorised medicines. In other cases, counterfeiters used these substances to produce 'fake' versions of commonly prescribed anti-anxiety drugs, such as diazepam and alprazolam, which were sold directly on the illicit online drug market [10]. Furthermore, some new BZDs have been identified mixed with other NPS (i.e., synthetic cannabinoids) or have been labelled as diazepam tablets but containing a new potent synthetic opioid [11]. Overall, some of the new BZDs have been historically approved and marketed for use in some countries (i.e., phenazepam); whilst others have been previously investigated and may be found in some patent literature but subsequently not marketed; finally, the remaining ones represent completely new compounds [11]. Consequently, as an increasing number of BZD derivatives have appeared on

the NPS market, many of them associated with hospitalizations and fatalities, several countries worldwide have placed some of these substances under national control [10-11]. For example, in Europe, NPS belonging to the BZD class have been placed under national control in countries such as Denmark, Finland, Sweden, Switzerland, Turkey and the United Kingdom. In South-East Asia, the Republic of Korea is also reported to have placed diclazepam under national control and in the Middle East, the United Arab Emirates have placed diclazepam, and etizolam, flubromazepam and pyrazolam under national control [11]. Indeed, the WHO's Expert Committee on Drug Dependence will be reviewing both Etizolam and Flualprazolam at its 42nd meeting 21-25 October 2019, with a view to bringing these under international control [12]

Therefore, the present comprehensive overview aims at providing an up-to-date insight into the world of new/designer/synthetic BZDs recently marketed in NPS marketplaces, by investigating and collecting data coming from the literature so far published and the web as well, from pharmacological, toxicological and clinical points of view.

2. Materials and Methods

A comprehensive overview was carried out by using the EMCDDA/EDND database regularly monitored and analysed by **a team member of** our research team, by specifically looking at the so-called 'new benzodiazepines' so far marketed (last update: 25 September 2019). For each **BZD** here identified and selected, a PubMed/Medline search was also conducted in order to evaluate (if any) literature published (particularly, case-reports). **Two team members of our research team** combined the search strategy of free text terms and exploded MESH headings for the topics of Benzodiazepines and Novel Psychoactive Substances as following: ((*Benzodiazepines) [*Title/Abstract]) AND (*Designer* [Title/Abstract])) and for each of the 29 BZDs here identified (***Table 2***). Secondary searches were performed using the reference list of included articles and relevant systematic reviews. All articles published without time and/or language restriction were selected. Working independently and in parallel, **two reviewers of our research team** read the papers and determined whether they provided data on 'new benzodiazepines'. To be included in the present overview, studies were required to meet the following criteria: a) empirical and peer-reviewed study; b) at least an abstract with estimates **(for those papers not found in full text and/or with full text but not in English)** and/or full results published in English; c) investigated 'new benzodiazepines'. Studies evaluating 'classical BZDs', even though containing data on abuse and/or misuse were correctly excluded as not relevant to the aims of the present paper. As limited information is available, non-systematic review, reviews, letters to editors and meta-analyses were also considered for retrieving data (if available). **Two team members of our research team**, independently extracted the data. Disagreements were resolved by discussion and consensus with **a third member of the team.** Data were collected using an ad-hoc developed data extraction spreadsheet. ***Table 2*** **provides a summary of data collected by the present comprehensive review.**

However, given the limitation of peer-reviewed data published so far, a preliminary nonparticipant multilingual qualitative study of a **list of websites and other online resources (i.e. e-newsgroups, chat-rooms, bulletin boards, and e-newsletters), specifically addressed to psychonauts and NPS consumers,** was additionally conducted in order to obtain more data (in terms of clinical, pharmacological and toxicological effects) about the 29 BZDs selected and analysed here. A systematic Internet search was conducted on Google® which included the following keywords: '*benzodiazepine name*' and/or possible acronyms, street names etc. plus '*to buy*', '*experience*', '*trip*', '*legal high*', '*abuse', 'misuse'*. The first 5 pages recorded per search term and search engine were consequently selected and analysed only if relevant in terms of information and data provided regarding to '*new/designer BZDs*'. Within the time frame January–September 2019, data were collected **from 12 websites**. Confidentiality measures applied to the dataset included storage in an online, password-protected computer and removal of screen pseudonyms, URLs, country and city identifiers. Some 2,900 fora

threads were screened. After removal of Web pages which were either duplicates or nonrelevant to the aims of the study, 268 fora threads were used to retrieve and analyse the data presented here.

Ethical approval for the study was granted by the Department of Pharmacy Ethics Committee at the University of Hertfordshire (December 15, 2010, reference code PHAEC/1042), with further extensions of the approval granted in November 2013 and February 2019 (Protocol number: aLMS/SF/UH/02951(2).

All designer BZDs are here described and discussed according a chronological order of appearance on the online drugmarket and according to the notification sent out to the EMCDDA.

3. Results

3.1. Phenazepam

Phenazepam is a long-acting BZD, belonging to the 1,4-BZDs, the same family as diazepam, oxazepam and temazepam, which was developed in the 1970s for the treatment of epilepsy, alcohol withdrawal syndrome, insomnia, anxiety, and as premedication in anesthesia procedures, which is currently the most prescribed BZD in Russia since 1978 [13-19]. Phenazepam has not been licensed in other European countries. Phenazepam is currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs. Phenazepam is controlled in Estonia, Latvia, Lithuania, Moldova, Norway, Sweden, and the Republic of Ireland [16; 20-22]. Whilst it is covered by prescription legislation in Estonia, Latvia, Lithuania, the Russian Federation and Belarus [16; 22]. Following the UK Advisory Council on the Misuse of Drugs (ACMD) advice, the Home Office imposed a ban (dated 22 July 2011) under the Open General Import License on the importation of phenazepam [23-25]. Following the ACMD recommendation, phenazepam became controlled in the UK, like other BZDs, as a Class C drug from June 2012. The recreational/unauthorized use of phenazepam has been reported during recent last years, particularly in the USA, New Zealand, and some European countries, particularly in Scandinavian countries (i.e., Finland, Norway and Sweden) [16; 26-28].

From a pharmacological point of view, phenazepam is generally more potent than diazepam (5-10-fold) and possesses more severe and persistent side-effects (up to 5 days-3 weeks), by having a long elimination half-life of around 60 hours after ingestion [16; 26; 29-32]. Phenazepam has an active metabolite 3-hydroxyphenazepam which is as well 5- to 10-fold more potent than diazepam. Various fatal cases have been reported following the intake of phenazepam as well as reports of abuse, especially in combination with opioids and/or other sedatives [19; 21; 27; 32-43]. **The most frequently reported causes of poisoning occurring in children in Moscow appear to be BZD-related, mainly involving cases of phenazepam intake** [44]. Reported side-effects include amnesia, drowsiness, dizziness, somnolence, difficulty in waking up, muscle weakness, headache, weakening of attention, incoordination, blurred vision, slurred speech, ataxia, and **muscle weakness** [45]. At high doses, delirium and psychosis-like behaviour have been reported [46]. Phenazepam and its active metabolite are both $GABA_A$ **receptor positive allosteric modulators** [47-48]. In Russia and in other countries in which is legally marketed, phenazepam is available as 0.5-1 mg tablets, injectable solutions (0.1%, 0,3%) and transdermal patches, with a usual therapeutic oral dosage of 0.5 mg 2-3 times per day, and a maximum tolerated dose of 10 mg daily [33; 49-50]. In the NPS market, phenazepam has been sold as a powder, tablets, spiked in blotters similar to LSD, or, in USA, sold as an air freshener known as "Zannie" which can be administered by spraying into the mouth [45]; it is easily available via the Internet, often produced in China [32; 51-52]. The main routes of administration (ROA) reported include orally (most common), snorted, inhaled, administered transdermal or rectally, or injected (after crushing the tablet) [53]. Phenazepam has been reported to be used to enhance the euphoric effects of opioids (particularly, to "boost" methadone doses), to alleviate withdrawal or abstinence syndrome (i.e., between heroin 'fixes'), to potentiate the effects of alcohol and to temper/balance cocaine 'highs' [28; 50; 54].

The Scottish police seized phenazepam for the first time in October 2008, sold as fake 'diazepam'; then it appeared again in January 2011 in North Wales and in March 2011 in Germany [21]. Furthermore, phenazepam appeared to be present mixed in some packages containing synthetic cannabinoids, JWH-018, JWH-073, JWH-122 and JWH-250 [55-57]. There are several anecdotal reports from psychonaut fora which describe it as "*a very long lasting, potent and subtle benzodiazepine (…)*" [52; 54]. In particular, a low dose is reported to range from 0.5 to 1 mg, a typical dose is 1-2 mg, and a high dose is 2-4 mg or more [58]. Onset of symptomatology is reported after 15-60 minutes, effects may last more than 18 hours and after-effects more than 36 hours [58].

3.2 Etizolam

Etizolam is a short-acting BZD, belonging to the thienotriazolodiazepine family (in which a diazepine ring is fused to a thiophene ring, instead of a benzene**)**, marketed in some countries (i.e., Japan), which is used for the treatment of insomnia, anxiety disorders, and withdrawal symptomatology [59]. The recommended dosage of etizolam for **medical use** is approximately 1 mg to 1.5 mg daily up to a maximum of 4 mg daily [60]. It has elimination kinetics between those of short-intermediate derivatives and ultra-rapidly eliminated BZDs. Etizolam is pharmacologically similar to diazepam [60]. It has been implicated in fatalities [61]. Perhaps no more so than in Scotland. The number of deaths registered there involving etizolam has reached a crisis point; rising gradually from 1 in 2012, 8 in 2013, 37 in 2014, and to 43 in 2015. However, the number in 2016 was 225, with 300 in 2017 but an unprecedented 551 in 2018, out of a total of 1313 drug-related poisoning **deaths [62]. There are no further data about clinical, pharmacological or toxicological properties. Etizolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Etizolam was first reported to the EMCDDA by the UK's Hampshire police in September 2011 in a seizure of tablets bought on line. Subsequently, powders, as well as 'blotters' (similar to LSD paper doses) were reported [21]. There are several anecdotal reports from psychonaut fora which describe it with a "*high potency which allows an effective dose of a few milligrams to be present on a paper dose (…)*" [52; 54]. In particular, a low dose is 0.5-1 mg, a typical dose is 1-2 mg, and a high dose is 2-4 mg or more [58]. Onset of symptomatology occurs in 10-40 minutes, effects last 5-8 hours and after-effects for 6-24 hours [58].

3.3. Pyrazolam

Pyrazolam is a triazolo-BZD with apparently very little information, structurally similar to alprazolam but is brominated rather than chlorinated and contains a pyridinyl group instead of a phenyl group. It was first developed and patented by Hoffman-La Roche in 1979 in a patent [63]. However, pyrazolam is the first BZD on the NPS market that is not marketed anywhere in the world by a pharmaceutical company for medical purposes [63]. It has been sold as tablets that contain 0.5 mg of active compound per tablet. From a pharmacological point of view, pyrazolam is generally more potent than diazepam (12-fold) and has an elimination half-life of around 6 hours after ingestion [63]. **There are no further data about clinical, pharmacological or toxicological properties. Pyrazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Pyrazolam was first reported in a seizure of tablets in a mail package on 3 August 2011 by Finnish Customs officials [63-64]. There are limited anecdotal reports from psychonaut fora which describe it as "*quite sedating, amnesic and loss of inhibition at higher doses (…) anxiolytic effect at lower doses (…)*" [52; 54]. In particular, a light dose is 1-2 mg, a typical dose is 2-3 mg, and a high dose is 3-4 mg [58]. Onset of symptomatology occurs in 10-15 minutes, effects may last 5-8 hours and after-effects for 1-12 hours [58].

3.4. Flubromazepam

Flubromazepam is a long-lasting BZD, structurally similar to phenazepam, from which it differs due to substitution of a fluorine atom instead of a chlorine atom, and to triazolam and pyrazolam. It does not appear to be licensed for **medical use.** Flubromazepam was first described in 1962 when it was noted to be several times more potent than chlordiazepoxide, the reference substance used in several assays [65]. Derivatives of this substance may be used as antivirals [66]. Pharmacokinetic data suggest an elimination half-life of about 100 hours and anticonvulsant properties [63]. Published literature described a fatal case of poisoning by the synthetic opioid U-47700 in combination with flubromazepam in a 24-year-old man [67]. Furthermore, three hospitalisations from acute exposure have been reported in the US and 33 in Sweden between 2012-2017 [63; 68-71]. **There are no further data about clinical, pharmacological or toxicological properties. Flubromazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Flubromazepam was first identified in a sample of capsules analysed by a German university forensic institute in March 2013 [69-70; 72-73]. There are several anecdotal reports from psychonaut fora which describe it as "*of extreme duration, with effects for larger doses reaching up to three days*" [52; 54]. In particular, a low dose is 2-4 mg, a typical dose is 4-8 mg, and a high dose is 8-12 mg or more [58]. Symptomatology occurs in 15-90 minutes, effects may last 12-18 hours and after-effects for more than 36 hours [58].

3.5. Diclazepam

Diclazepam is the 2'-chloro derivative of diazepam and a positional isomer of 4-chlorodiazepam. It was first synthetised by the Hoffman-La Roche in 1960 [74] and recently appeared in the 'grey drug market' as an alternative to etizolam [10]. Babbini et al. [75] reported a potency of approximately 4-8 times higher than diazepam in terms of reducing motor activity and conflict behaviour in rats whilst Sternbach et al. [76] described a potency similar to diazepam regarding to muscle relaxant and sedative effects in mice and twice as potent than diazepam investigating the same effects in cats [76]. It does not show differences in the behavioural activity if given to monkeys, compared to diazepam [77]. Diclazepam has a long half-life of approximately 42 hours and its pharmacokinetic profile follows a biphasic elimination [7]. **There are no further data about clinical, pharmacological or toxicological properties. Diclazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Diclazepam was first identified in a sample of tablets analysed by a German university forensic institute in August 2013 [69-70; 72]. There are several anecdotal reports on psychonaut fora which describe it as "*sedative and hypnotic*" with similar effects to diazepam, even though "*10-fold times more potent and with an intermediate half-life*" [54]. In particular, a low dose is 0.25-1 mg, a typical dose is 1-2 mg, and a strong dose is 2 mg or more [58]. Symptomatology occurs after 15-90 minutes, effects may last 8-12 hours and after-effects for 1-24 hours [58].

3.6. Alprazolam triazolobenzophenone derivative

The Alprazolam triazolobenzophenone derivative represents a product of hydrolysis, under acidic conditions, of alprazolam and, hence, a metabolite of alprazolam as well. At neutral pH, it rapidly converts to alprazolam. It was firstly developed by the Upjohn Company in the 1980s as a water-soluble pro-drug of alprazolam for the parenteral (intravenous or intramuscular) ROA [78]. **There are no further data about clinical, pharmacological or toxicological**

properties. Alprazolam triazolobenzophenone is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.

Alprazolam triazolobenzophenone was been firstly identified in a seizure of 1000 grams of white powder, seized at Madrid Airport in March 2014 by Customs authorities in a package that had arrived from India; it also contained paracetamol. The compound was identified and characterised using the **gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR)** by the Spanish National Focal Point [79]. There are limited anecdotal reports from psychonaut fora but it is supposed to exert an effect similar to that of alprazolam [54].

3.7. Meclonazepam

Meclonazepam represents the 3-methyl-derivative of clonazepam, hence, it has been supposed it exhibits similar sedative, anxiolytic and anti-parasitic effects [80]. Its synthesis **was** first developed and patented by Hoffman-La Roche in 1977 [81]. Its pharmacology has been investigated in clinical trials as an anxiolytic and as a schistosomicidal compound able to treat parasitic infections by *Schistosoma haemayobium* and *Schistosoma Mansori* [81-84]. Drowsiness, dizziness, slurred speech, ataxia, muscle weakness, reduced mental alertness and lateral nystagmus have been described as the main side-effects [82]. The effects appear to be dose-dependent with a narrow therapeutic range (0.3-0.4 **mg/kg**) [82]. Doses above **0.4 mg/kg** have been described as causing severe adverse drug effects, with the most pronounced effects within 3 hours after oral intake of more than 1 mg of meclonazepam and amnesia after a 4-mg dose [82; 85]. An anxiolytic potency 3-fold that of diazepam has been reported [83]. From a pharmacokinetics perspective, a plasma t ½ of approximately 40-80 hours is reported [83; 86]. **There are no further data about clinical, pharmacological or toxicological properties. Meclonazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Meclonazepam was first identified in a seizure of 145 capsules in May 2014 by Swedish police in Eskilstuna. The substance was identified by the Swedish National Laboratory of Forensic Science (SKL) using GC-MS and NMR analyses [69-70; 79]. There are several anecdotal reports from psychonaut fora which describe it as "*relatively fast sublingual onset*" which gives it a strong '*anti-panic effect*' [54]. In particular, a low dose is 0.25-0.5 mg, a typical dose is 0.5-1 mg, and a high dose is 1-2 mg or more [58]. Onset of symptomatology is in 20-45 minutes, effects may last 8-12 hours and after-effects for 8-48 hours [58].

3.8. Deschloroetizolam

Deschloroetizolam is a thienodiazepine, structurally similar to etizolam, from which it differs due to the absence of chlorine on the benzene ring; triazolam and alprazolam [87]. Deschloroetizolam is supposed to have a rapid onset of action, even though it appears to be half as potent as its parent compound etizolam with a duration twice as long, as supposed by the loss of the chlorine atom [76; 87-88]. Sedation, respiratory distress, muscle relaxation, amnesia, dizziness, thought deceleration, disinhibition, delusion of sobriety, and dream potentiation have been described following its intake [87]. Synthesis of **deschloroetizolam** was first described in a 1988 patent [88-89]. **There are no further data about clinical, pharmacological or toxicological properties. Deschloroetizolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Deschloroetizolam **was first** identified in a UK seizure of blue tablets on August 2014. The substance was identified by the WEDINOS Project in Wales using **TOF (time-of-flight mass spectrometry) analysis** [69; 79]. There are limited anecdotal reports from psychonaut fora which describe it as "*longer acting and slightly less potent than*

etizolam" [54]. In particular, a low dose is 2-4 mg, a typical dose is 4-6 mg, and a strong dose **is 6-12 mg** [58]. Onset of symptomatology happens in 1-5 minutes, effects may last 8-10 hours and after-effects for 1-8 hours [58].

3.9. Flubromazolam

Flubromazolam is a substituted BZD, structurally related to pyrazolam from which it differs due to the substitution of a 2-fluorophenyl instead of a 2-pyridinyl group at position 6. Moreover, it is the triazolo-analogue of flubromazepam and it is structurally related to alprazolam and triazolam [90-93]. The substance has been researched in the patent literature for its anxiolytic properties and decreased sedative, hypnotic, and ataxic side-effects, but it does not appear to be licensed for **medical use**. Łukasik-Głebocka et al. [94] reported a case of severe intoxication following the intake of flubromazolam in an individual who presented with deep coma, bilateral pinpoint unreactive pupils, acute respiratory failure and hypotension complicated by hypoxic cerebral ischaemia. Huppertz et al. [90] reported muscle relaxation, sedation, difficulty following and participating in conversation and partial amnesia in a healthy volunteer following intake of 0.5 mg of flubromazolam. A case-report described a 36-year-old male affected with a schizoaffective disorder, opioid use disorder, seizures, anxiety and a posttraumatic stress disorder who presented to an inpatient facility and reported flubromazolam abuse [93]. **There are no further data about clinical, pharmacological or toxicological properties. Flubromazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Flubromazolam was first identified in a sample of 10 white rectangle shaped tablets labelled "XANAX", seized in Malmö by Swedish police in September. The substance was identified by the National Laboratory of Forensic Science (SKL) by using GC-MS and NMR [79]. There are several anecdotal reports from psychonaut fora which describe "*mild anxiolytic and skeletal muscle relaxant effects*" at low doses as 0.1 mg whilst "*significant sedation*" at doses of 0.5 mg [51]. Moreover, it has been described as "*hard to dose*" due to its unpredictable dose-response effects [52; 93]. In particular, a 'threshold' dose of 80 μg is described, with a low dose being 100-200 μg, a typical dose is 200-400 μg, and a high dose is 400-600 μg or more [58]. Onset of symptomatology occurs in 20-45 minutes, effects may last 6-12 hours and after-effects for 6-24 hours [58].

3.10. Nifoxipam

Nifoxipam represents the 3-hydroxy-desmethyl-derivative (active metabolite) of the hypnotic BZD flunitrazepam, from which it differs due to the presence of an additional hydroxyl group and the deletion of a methyl group. Moreover, nifoxipam is also the 3-hydroxy metabolite of fonazepam [95]. It is normally consumed in tablet form, even though is also available in powder form. Its typical ROA is orally or sublingually [95]. Little is known about the pharmacology and toxicology of nifoxipam. Nifoxipam likely possesses a pharmacological activity similar to flunitrazepam, by binding to the $GABA_A$ receptor, and with similar side-effects and toxicity [95]. Nifoxipam is extremely physically and psychologically addictive and presents cross-tolerance with all BZDs, thereby reducing their pharmacological effects [95]. **There are no further data about clinical, pharmacological or toxicological properties. Nifoxipam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Nifoxipam was first identified in a seizure of 20 brown tablets made by the Swedish Police in April 2014. The substance was analytically confirmed by GC-MS, **LC-MS (liquid chromatography-mass spectrometry)** and NMR analysis by the Swedish National Laboratory of Forensic Sciences [69; 79]. In December 2014, four round, light-brown tablets marked as 'nifoxipam 1 mg' were sent from the UK to Finland where they were seized and nifoxipam was

analytically confirmed by GC-MS and LC-MS/MS analysis [9-10]. Finally, in January 2015, the Norwegian Federal Police seized 101 brown tablets found in a mail package sent from the UK to Norway and nifoxipam was analytically confirmed by GC-MS analysis [10; 95]. There are several anecdotal reports from psychonaut fora which describe "*a greater hypnotic effect*" [51], anxiety relief, euphoria within 10-15 minutes after intake of 1 mg of nifoxipam along with a drink [52]. A low dose is 250-500 μg, a typical dose is 500-1000 μg, and high dose is 1000-2000 μg or more [58]. Onset of symptomatology occurs after 10-75 minutes, effects may last 10-18 hours and after-effects for 1-24 hours [58].

3.11. Clonazolam/Clonitrazolam

Clonazolam is a triazolo BZD, structurally similar to flubromazolam, from which it differs due to possessing a nitro group in the 8th position and a 2-chlorophenyl group instead of a 2-fluorophenyl group. Clonazolam is the second most common single agent exposure responsible for 50 cases (21% of the sample) of BZD intoxications reported to the National Poison Data System (USA) in 2014-2017, according to a study by Carpenter et al. [64]. The most frequently reported motivations for intake are reported as: misuse (12%), abuse (60%) and suspected suicide (20%), being acute intoxication the most commonly described (78%). Subjects who took clonazolam described the onset of lethargy/drowsiness (68%), slurred speech (16%), tachycardia (14%), confusion (10%), agitation/irritability (6%), ataxia (6%), hypotension (6%), coma (6%), and bradycardia (6%). Most patients were treated with fluid infusion (34%), oxygen (12%), intubation or ventilation (6%), flumazenil (6%) and antiemetics (4%). Eleven patients were admitted to a noncritical care unit, ten to a critical care unit while 17 were treated and the released; only five cases were admitted to a psychiatric facility, by reporting minor or moderate sequalae in 45% and 35% of cases, respectively [70]. **There are no further data about clinical, pharmacological or toxicological properties.**

Clonazolam was first synthesised in the 1970s by the Upjohn Company [96]. Clonazolam was first identified in a seizure of 25 yellow tablets containing a white powder by the Swedish Police on 16 October 2014. The substance was analytically confirmed by GC-MS and NMR analysis [69; 79]. Clonazolam was classified as a Class C drug by the May 2017 amendment to the Misuse of Drugs Act 1971 in the UK [97]. There are several anecdotal reports from psychonaut fora which describe "*a total relaxing and anxiolytic effect, a moderate sedation*" [54]. A threshold dose is described as being 50-75 μg, a low dose is 75-200 μg, a typical dose is 200-400 μg, and a high dose is 500-1000 μg or more [58]. Symptomatology occurs in 10-30 minutes, with effects lasting 6-10 hours and after-effects for 1-12 hours [58]. The most commonly reported ROA is oral, with a described potency 10-fold higher than lorazepam 1 mg [98]. Moosmann et al. [8] reported that clonazolam, due to its higher potency, can cause sedation and amnesia at oral doses as low as 0.5 mg which are extremely difficult to measure for users handling bulk materials, and, being tablets often vary greatly in terms of clonazolam content, this can frequently lead to unintended overdosing and lead to drug facilitated crimes [99].

3.12. Adinazolam

Adinazolam is a short-acting BZD belonging to the triazolo-BZD class. The half-life of adinazolam is indicated as less than 3 hours [**100**]. Three hours was also considered the time of peak onset for adinazolam, i.e., the time after administration of the substance where subjective effects were most pronounced [101]. In-vivo metabolism of adinazolam occurs mainly through the liver and results in the formation of active metabolites, mostly *N*-demethyl-adinazolam (NDMAD) [102]. Alpha-hydroxy-alprazolam and estazolam are also metabolites of adinazolam [103]. Adinazolam has a high affinity for the $GABA_A$ receptor [102]. In vitro, both adinazolam and NDMAD bind to central BZD-receptors but NDMAD has an approximately 25-fold higher activity than adinazolam [102; 104-106]. The molecule has been studied for the treatment of depression, panic disorder, general anxiety and status epilepticus [106-108]. It can

be used to induce sedation and anterograde amnesia (whereby it reduces the memory of an event following its administration) [100; 109]. Ataxia, dysarthria, weakness, diminished reflexes, confusion, coma and a paradoxical excitement in children have been reported, in addition to signs of overdose **[100]**. A human study comparing the subjective effects and abuse potential of adinazolam (30 mg and 50 mg) with diazepam, lorazepam and a placebo showed that adinazolam causes the most "*mental and physical sedation*" and the greatest "*mental unpleasantness*" [101]. The same study notes that despite reports of "*unpleasantness*" the participants of the study rated the substance of high "street value", capable of producing "*physical and mental highness*" according to the Addiction Research Criteria Inventory (ARCI) [101]. **There are no further data about clinical, pharmacological or toxicological properties. Adinazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Adinazolam was first identified in a sample of 1 gram of white powder collected by the Medical Centre in the Institute of Forensic Medicine at the University of Freiburg (Germany) on 5 September 2015. The substance was analytically confirmed by GC-MS analysis [70; 109]. A seizure of 105 tablets was reported shortly afterwards (8 September 2015) by the Swedish Focal point, following a seizure by the Swedish police in Gottenburg. The tablets were white in colour with the markings "D/CD" and weighed 0.35 grams on average. Moreover, the Swedish Poison Control Centre/STRIDA project reported a positive detection for adinazolam related to a hospital inquiry where an individual had taken "Xanor 2.0" (i.e., brand name for Xanax® in Sweden) [109]. Additionally, a sample of 5 g of adinazolam (as a white powder) was test-purchased on 18 September 2015 by the National Forensic Laboratory in Slovenia [110]. There are several anecdotal reports from psychonaut fora. A low dose is 5-15 mg, a typical dose is 15-30 mg, and a high dose is 30-50 mg or more [58]. Onset of symptomatology occurs after 10-25 minutes, effects may last 2-5 hours and after-effects for 1-16 hours [58].

3.13. Nitrazolam

Nitrazolam is a triazolo-BZD, structurally similar to clonazolam (previously notified on 30 December 2014), from which it differs by a chlorine atom on the ortho position of the benzene ring [111]. Its synthesis and activity were described in a 1976 patent [96; 112]. Animal studies indicate that nitrazolam can be several times more potent than diazepam **in preventing of electroshock-induced tonic-extensor convulsions** [111]. Moreover, nitrazolam appears to be less potent than clonazolam and triazolam [111]. Clonazolam may cause powerful sedation and amnesia at a total oral dose of 0.5 mg [88; 96; 113-115]. **There are no further data about clinical, pharmacological or toxicological properties. Nitrazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.**

Nitrazolam was first identified in a sample of a light brown powder on the 20 October 2015 by the Medical Centre, Institute of Forensic Medicine at the University of Freiburg, Germany. The substance was analytically confirmed by GC-MS and NMR [110-111]. There are several anecdotal reports from psychonaut fora which described mostly an "*anxiolytic and muscle relaxant effect […] with a low tolerance shows hypnotic effects. Amnesiac, but not a huge degree […] closer to etizolam than alprazolam*" [116]. A low dose is 0.5-1 mg, a typical dose is 1-2 mg, and a high dose is 2-3 mg or more [58]. Onset of symptomatology happens in 15-30 minutes, effects may last 5-10 hours and after-effects for 10-24 hours [58].

3.14. Metizolam

Metizolam is a thienodiazepine, structurally similar to etizolam, from which it differs by only a methyl ring in the thiophene moiety [117]. There are no data about clinical, pharmacological or toxicological properties. **Metizolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Metizolam was first identified in a sample of 20 light-blue round tablets by the Medical Centre, Institute of Forensic Medicine at the University of Freiburg, Germany on 25 September 2015. The substance was analytically confirmed by GC-MS and NMR. The Danish National Focal Point reported a seizure of 55 blue round tablets containing metizolam on the 30 October 2015 by Danish Customs and related to a package sent from the UK to a private address in Denmark [110]. There are limited anecdotal reports from psychonaut fora. It has been reported that metizolam causes effects similar to etizolam, even though it is half as potent and with around a 60% longer t ½ [51]. It has also been described as exerting hypnotic and sedative effects, and may cause amnesia and lowered inhibition if taken at higher dosages [116]. A low dose is 1-2 mg, a typical dose is 2-4 mg, and a high dose at 4-6 mg, whilst a heavy dose is 6 mg or more [58]. Symptomatology occurs in 30-90 minutes, with effects lasting 5-8 hours and after-effects for 10-30 hours [58].

3.15. Cloniprazepam

Cloniprazepam shares structural similarities with the previously notified BZD clonazolam (clonitrazolam) and meclonazepam. It has also been described as a prodrug for clonazepam [58]. **There are no data about clinical, pharmacological or toxicological properties. Cloniprazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Cloniprazepam was first identified in a seizure of 25 white capsules by Swedish Police in Sundsvall on 2 December 2015. The substance was analytically confirmed by GC-MS, **GC-IR (gas chromatography infrared spectrometry)**, **LC-HRMS (Liquid Chromatography-High Resolution Mass Spectrometry)** and NMR [70; 110; 118-119]. There are limited anecdotal reports from psychonaut fora. Cloniprazepam is usually sold online in 2.5 mg capsules and available is in packs of 20, 60, 120 and 240 and it appears to exert similar effects to clonazepam [51]. A low dose is 0.5-1 mg, a typical dose is 1-2 mg, and a high dose is 2-4 mg or more [58]. Onset of symptomatology occurs in 15-45 minutes, with effects lasting 6-9 hours and after-effects for 1-8 hours [58].

3.16. 3-hydroxyphenazepam

3-Hydroxyphenazepam is an active metabolite of both phenazepam (7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) and cinazepam [120-121]. It can be quantified by LC-MS/MS in a variety of post-mortem fluids (subclavian blood, femoral blood, cardiac blood, urine, vitreous humour) and tissues (thalamus, liver and psoas muscle) [122]; and by GC-MS (limit of detection: 1 mg/L) [29; 123]. In a study in which a 5-mg oral dose of phenazepam was given to healthy volunteers, 3-hydroxyphenazepam was detected in urine samples but not in blood samples [29]. In research investigating its distribution in the plasma and brain of mice tranquillising and anticonvulsive properties were reported [124-126]. It is a full γ- $GABA_A$ receptor **positive allosteric modulator** [73; 126-127]. 3-hydroxyphenazepam appears to be pharmacologically active with some 5- to 10-fold higher potency than diazepam, probably due to the bromine atom in the molecule [128]. In addition, 3-hydroxyphenazepam represents the main metabolite of levana (3-hydroxyphenazepam hemisuccinate) [125]. Researchers report that levana has a greater anticonvulsive effect than its metabolite 3-hydroxyphenazepam [125-126; 129]. **3-Hydroxyphenazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

The 3-hydroxyphenazepam molecule was first identified in a collected sample of white powder by the Medical Centre in the University of Freiburg, Institute of Forensic Medicine, Forensic Toxicology Department on 19 October 2015 [69; 110]. It was also detected in a seizure of 21 tablets (12 white tablets and 9 pale blue tablets) by Swedish police on 1 December 2015 in Varberg [69; 110]. The STRIDA project described a case-series of consecutive patients with admitted or suspected NPS intake afferent to emergency department of all Swedish hospitals in 2012-2016, of which eight cases had 3-hydroxyphenazepam implicated [69]. There are several significant anecdotal reports from psychonaut fora. A low dose is 0.5-1 mg, a typical dose is 1-2 mg, and a high dose is 2-4 mg [58]. Symptomatology occurs 30-90 minutes after oral and/or sublingual intake, with effects lasting 10-24 hours and after-effects for 2-24 hours [58]. The most commonly reported ROAs are oral and sublingually [51-52; 54].

3.17. Fonazepam

Fonazepam is structurally related to the internationally controlled substance flunitrazepam (aka 'Rohypnol®'), from which it differs only due to the absence of an N-methyl group [130]. Fonazepam is the desmethyl-derivative and one of the active metabolites of flunitrazepam [95; 130]. Therefore, it has been supposed to possess similar pharmacological and toxicological properties to flunitrazepam (i.e., hypnotic and pre-anesthetic effects) [95]. Furthermore, it also shares structural similarities with the previously notified BZD nifoxipam (3-hydroxydesmethylflunitrazepam), from which it differs by the absence of a hydroxy group. Fonazepam was included in research describing the synthesis of 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-ones by direct nitration of the corresponding unsubstituted BZDs [131]. The synthesis of fonazepam was first described in a 1963 patent by Hoffman-La Roche and in research determining 1,4-BZDs and -diazepin-2-ones in blood by Electron-Capture Gas-Liquid Chromatography (EC-GLC) [131-132]. Research into the binding affinity to $GABA_A$ receptors has been predicted for fonazepam (Ro 05-4435) using artificial neural networks [133]. Fonazepam was reported to have a binding affinity (log IC50) of 0.176 and a predicted value of 0.565 [95; 133-134]. **Fonazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Fonazepam was first identified in a sample of 51 tablets (27 white, 15 blue and 9 grey tablets) found in Lidköping, by Swedish police on 10 March 2016. The substance was analytically confirmed by GC-MS using a reference standard [95; 135]. In addition, it was also detected in a collected sample of 1 gram of white/yellow powder received from an online research chemical company based in China on 13 January 2016. The sample was collected by the Medical Center at the University of Freiburg, Institute of Forensic Medicine, Forensic Toxicology Department [10]. There are several significant anecdotal reports on psychonaut fora. Fonazepam is normally consumed in tablet (or in powder) form and administered in doses ranging from 0.5 to 3 mg [51-52; 54]. The most commonly reported ROAs are oral and sublingual [51-52; 54]. It is usually taken in association with other BZDs [52]. Fonazepam is a controlled substance on Schedule IV of the Controlled Substances Act in the U.S.A. as a derivative of flunitrazepam [95].

3.18. 4-chlorodiazepam

4-chlorodiazepam represents the 4-chloro-derivative of the internationally controlled substance diazepam, from which it differs due to the addition of a chloro substituent in the ***para*** or 4-position of the phenyl ring. It is a positional isomer of another designer BZD, diclazepam (Ro5-3448 or 2'-chlorodiazepam) [136]. First studies investigating **4-Chlorodiazepam** (aka Ro 5-4864) began in the mid-1960s and it was mentioned in a 1964 patent on '*Amino substituted benzophenone oximes and derivatives thereof*' [137]. The compound was researched for its anticonvulsant profile against experimental seizures in mice [138]. Initial clinical studies using healthy volunteers

indicated **that 4-Chlorodiazepam** had a pharmacological effect comparable to that of diazepam [139]. It was further investigated due to its binding and higher affinity to the translocator protein (TSPO), a peripheral-type BZD receptor, even though it does not bind to central-type BZD receptors [139-141]. Research in rodents indicates that 4-chlorodiazepam may exert analgesic, antidepressant, cardio-protective and neuro-protective effects [141-149]. A study by Viega *et al.* [145] indicated that there were several possible explanations for the neuro-protective effect of **4-Chlorodiazepam** including modulation of the mitochondrial transmembrane potential protecting the neural cells from damage by reactive species, prevention of apoptosis or regulation of steroid synthesis. **4-Chlorodiazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

4-chlorodiazepam has been first identified in a sample of 5 grams of off-white powder by the Slovenian National Forensic Laboratory in Ljubljana. The sample was purchased from the Internet as part of the RESPONSE project and was received on 10 May 2016, shipped from China. The substance was analytically confirmed by GC-MS, **HPLC-TOF (Time-of-Flight High Performance Liquid Chromatography)**, **FTIR-ATR (Spectrophotometry Infrared-Attenuated total reflectance**), GC-MS-IR-(condensed phase) and ion chromatography [9; 135; 152]. There are limited clinically significant anecdotal reports from psychonaut fora. It has been described as having pro-anxiety and pro-convulsive effects [54; 116].

3.19. Flunitrazolam

Flunitrazolam is a triazolo BZD, structurally related to the previously notified clonazolam (clonitrazolam), differing by the replacement of 2-chloro with 2-fluoro on the phenyl group. It is also the triazolo version of the internationally controlled substance flunitrazepam [87; 150]. Flunitrazolam was discovered in the 1960s but it has never been marketed [87]. No information about doses, effects, safety and tolerability has been published so far. However, based on its structural similarity to other triazolo-BZDs, it has been supposed that the potency of flunitrazolam is higher than of the already highly potent flunitrazepam [151]. A t ½ of around 8 hours in oral fluid is reported [87]. There are no further data on its pharmacological and/or toxicological profile so far. **Flunitrazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Flunitrazolam was first identified by an analytical laboratory in Germany on 6 October 2016, although there was seizure of 80 grey tablets in Sweden on 7 June 2016. The molecule has not been previously described in the scientific or patent literature [9; 109; 135; 152]. There are limited clinically significant anecdotal reports from psychonaut fora. A threshold dose is stated to be 0.3-0.4 mg, a low dose as 0.4-0.8 mg, a typical dose as 0.8-1.5 mg, and a high dose as 1.5-3 mg [58]. Onset of symptomatology occurs within 10-30 minutes after oral intake, with effects lasting 4-5 hours and after-effects for 1-16 hours; whilst after sublingual administration, symptoms start within 5-15 minutes, may last around 4-5 hours with after-effects present for 1-12 hours [58].

3.20. Bromazolam

Bromazolam is a triazolo-BZD structurally related to flubromazepam, from which it differs due to the absence of a fluorine in the 2-position on the phenyl ring. Bromazolam is also structurally similar to pyrazolam, where the pyridinyl group has been replaced with a phenyl group. Moreover, bromazolam is the brominated version of the internationally controlled substance alprazolam [115; 153]. **There are further data about clinical, pharmacological or toxicological properties. Bromazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Bromazolam was first identified in a sample of 0.74 grams of yellow powder seized by Swedish Customs in Stockholm on 3 August 2016. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS, **GC-IRD (Gas Chromatography with infrared detection)**, LC-HRMS and NMR [9; 135]. There are limited clinically significant anecdotal reports from psychonaut fora. A low dose is 0.5-1 mg, a typical dose is 1-3 mg, and a high dose is 3-5 mg or more [58]. Symptomatology onset occurs 15-45 minutes after oral intake, effects may last 5-8 hours and after-effects for 1-12 hours after administration [58].

3.21. Norfludiazepam

Norfludiazepam is a BZD, structurally related to the internationally controlled substance diazepam, from which it differs due to the addition of a fluoro substituent in the ***ortho*** or 2-position of the phenyl ring and by the absence of the methyl group attached to the amide in diazepam. It is also structurally related to the previously notified 4-chlorodiazepam (Ro 5-4864), from which it differs due to the replacement of the chlorine in the 4-position on the phenyl ring with a fluorine in the 2-position and the methyl group attached to the amide in 4-chlorodizepam is also absent [74]. It is the active metabolite of flurazepam and fludiazepam and is used in the synthesis of midazolam, either as an intermediate with 2-amino-5-chloro-2'-fluorobenzophenone as the starting substance or as the starting substance itself [74; 136; 154]. Norfludiazepam has a significantly longer half-life compared to flurazepam (up to 24-74 hours) [154]. Research into norfludiazepam began in the mid-1960s [74]. No further pharmacological and toxicological data are available. **There are no further data about clinical, pharmacological or toxicological properties. Norfludiazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Norfludiazepam was first identified in 5 grams of white powder seized by Swedish Customs in Stockholm, on 22 November 2016, and in 50 orange tablets and in 1 gram of white powder by the Medical Center – University of Freiburg, Institute of Forensic Medicine, Forensic Toxicology Department, Freiburg Germany, on 4 March 2016. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS [9; 135], There are no clinically significant anecdotal reports from psychonaut fora describing clinical effects of norfludiazepam so far.

3.22. Ro 07-4065

Ro 07-4065 is structurally related to the internationally controlled substances diazepam and fludiazepam. Ro 07-4065 differs from diazepam due to the addition of fluoro substituents in both the 2- and 6-positions on the phenyl ring and differs from fludiazepam due to the additional fluoro-substituent in the 6-position on the phenyl ring. It is also structurally related to norfludiazepam (Ro 5-3367), formally notified to the EMCDDA in January 2017, from which it differs due to the additional fluoro-substituent in the 6-position on the phenyl ring and due to the addition of a methyl group attached to the amide [10; 155]. Despite it being previously described in a 1972 patent, it is an extremely newly marketed BZD, mainly used as a research tool to help determining the shape and function of the GABA receptor complex [133-134; 156-157]. There is limited published information on its pharmacology and toxicology. The binding affinity of Ro 07-4065 to $GABA_A$ receptors has been predicted using in silico methods, such as for example artificial neural networks, and being reported as 0.613 [133-134]. **There are no further data about clinical, pharmacological or toxicological properties. Ro 07-4065 is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Ro 07-4065 was firstly identified in 1 gram of pale beige powder seized by Swedish Customs at FedEx Arlanda, Stockholm, on 14 March 2017 and notified as an NPS by Sweden to the EMCDDA in May 2017. The substance originated

by China and the sample was declared as a "sample for research" [155]. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS, GC-IRD, LC-HRMS and NMR [11; 135]. There are no clinically significant anecdotal reports from psychonaut fora describing clinical effects of Ro 07-4065 so far.

3.23. Thionordazepam

Thionordazepam is structurally related to internationally controlled nordazepam and alprazolam. Thionordazepam differs from nordazepam due to replacement of the oxygen with a sulphur and it differs from alprazolam due to the absence of the 1,2,4-triazole moiety [158]. It was previously described in a 1963 patent by Hoffman-La Roche [158]. Thionordazepam is used in the synthesis of alprazolam [159-160]. The analysis and identification of the starting material and synthesis-related intermediates for alprazolam, including thionordazepam, using high performance thin layer chromatography is reported in the literature [159]. There is no information available on the pharmacology and toxicology of thionordazepam. **There are no further data about clinical, pharmacological or toxicological properties. Thionordazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Thionordazepam was first identified in 2 grams of pale-yellow powder seized by Swedish Customs in Stockholm on 20 June 2017. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS, GC-IRD, LC-HRMS and NMR [11]. There are no clinically significant anecdotal reports from psychonaut fora describing clinical effects of thionordazepam so far.

3.24. Methyl-clonazepam

Methylclonazepam is a 1,4-BZD, structurally related to clonazepam, being its *N*-methyl derivative, and to internationally controlled flunitrazepam, from which it differs due to the substitution of the fluorine atom present in flunitrazepam with a chlorine atom [131]. Methylclonazepam also shares structural similarities with the previously notified meclonazepam, diclazepam and cloniprazepam [161-163]. Synthesis of **Methylclonazepam** was originally described by Sternbach et al. [131]. Behavioural effects of methyl clonazepam were compared with diazepam in rats and mice [164]. Methylclonazepam showed relatively potent muscle relaxant and extremely potent anti-pentetrazol convulsing action as compared to diazepam, even though it has been reported to be approximately 5-times more potent than diazepam in impairing rotarod performance in mice [164]. Methylclonazepam exerted muscle relaxant action in the rotarod method in rats and mice like clonazepam and nitrazepam and an anticonvulsant action like clonazepam [165]. Overall, it possesses a wider pharmacological spectrum than clonazepam, is almost equal in potency to nitrazepam and is more potent than diazepam [165]. Methylclonazepam at a dose of 2.5 mg/kg showed depressant effect on the gamma motor activity in rats. The depressant effects of a dose of 5.0 mg/kg lasted for more than 60 minutes [166]. Methylclonazepam produced sedation with a general drowsy pattern in the electroencephalogram in rabbits [167]. Furthermore, it has been also reported to exert both facilitative and depressive effects on paradoxical sleep in cats, depending on the dose [168]. From a pharmacokinetic point of view, methylclonazepam has a long plasma t ½ (40 hours) [83]. A double-blind, randomised cross-over study recruiting 18 inpatients affected with Generalized Anxiety Disorder compared daily flexible doses (3-6 mg) of methylclonazepam vs 2.5 mg lorazepam vs placebo, by showing highly significant superiority of both BZDs over placebo and a significant superiority of methylclonazepam over lorazepam on the Hamilton Anxiety scale ($p<.001$), Clinical Global Impairment (CGI)($p<.01$), without any significant differences in side-effects [83]. **There are no further data about clinical, pharmacological or toxicological properties.**

Methylclonazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs.

Methylclonazepam was been first identified in 100 grams of pale-yellow powder seized by Swedish Customs in Stockholm on 8 November 2017. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS, GC-IRD, LC-HRMS and NMR [11]. There are no clinically significant anecdotal reports from psychonaut fora describing clinical effects of methylclonazepam so far.

3.25. Fluclotizolam

Fluclotizolam is a thienodiazepine, where the diazepine ring is fused to a thiophene, instead of to a benzene ring, structurally related to internationally controlled brotizolam from which it differs in the halogen substituents at the tiophene and phenyl ring. Moreover, fluclotizolam also shares structural similarities with etizolam, formally notified to the EMCDDA in December 2011, from which it differs due to the replacement of a phenyl ring at the thiophene. Fluclotizolam was mentioned in a 1974 patent on thienotriazolodiazepines [169]. **There are no data about clinical, pharmacological or toxicological properties. Fluclotizolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Fluclotizolam was firstly seized in 94 pale green tablets by Swedish police in Gällivare, on 26 October 2017. The substance was analytically confirmed by the Swedish National Forensic Centre using GC-MS, GC-IRD, LC-HRMS and NMR [11]. It was also identified in 10 blotters seized by Danish customs at the Copenhagen International Post Office on 25 October 2017 [11]. There is no information available on the pharmacology and toxicology of this substance, as there are no published reports so far. Based on its chemical structure and similarity to brotizolam and etizolam, the substance is expected to have sedative hypnotic effects [170]. There are limited clinically significant anecdotal reports from psychonaut fora. A low dose is 0.25 mg, a typical dose is 0.25-0.5 mg, a high dose is 0.5-0.75 mg, whilst a heavy effect is experienced after more than 0.75 mg [58]. Caution is strongly recommended at higher doses, with 2 mg being considered a '*blackout dose'* [171]. Onset of symptomatology occurs 10-30 minutes after oral intake, effects may last 6-14 hours and after-effects for 1-36 hours after administration [58]. There are conflicting anecdotal reports on its dosage, though claims have been made that it has an approximately 3-fold higher potency and a shorter t ½, compared to etizolam [51; 58; 116; 171].

3.26. Tofisopam

Tofisopam is an atypical 2,3-benzodiazepine, which contains a stereogenic centre. Hence, it possesses owns a S- and a R-enantiomer form [172-173]. Tofisopam is a BZD first developed in Hungary and authorised in some European countries, marketed in the racemate form under the name Grandaxin®, orally administered at 300 mg daily for the treatment of neurotic and somatic disorders associated with tension, anxiety, vegetative disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome [174-175]. Moreover, tofisopam is marketed in other international countries, such as Japan, India, Russia etc. [176-177]. Pellow et al. [178] described its behavioural and biochemical profile, in both animals and humans. Tofisopam does not act on the BZD site of the GABA receptor but has a good anxiolytic activity without having appreciable sedative, anticonvulsant, amnestic, or muscle-relaxant effects in humans [179-180]; whilst it completely lacked anxiolytic and anticonvulsant properties in animals [178]. In addition, it appears to exert mixed dopamine agonist and antagonist-like properties in several *in vivo* and *in vitro* animal tests [181]. Moreover, under some circumstances, tofisopam may demonstrate stimulant properties as well [178; 182]. Tofisopam has multiple selective phosphodiesterase (PDE)-inhibiting actions (i.e. at PDE_{4A1}, PDE_{10A1}, PDE_3 and

PDE_{2A3}) which are being actively evaluated for managing negative and cognitive symptoms of schizophrenia [176; 180; 183-184]. Furthermore, it does not impair psychomotor and intellectual performance, like other BZDs and it has a potent capability in alleviating vegetative symptoms accompanying anxiety disorders [182; 185-188]. Due to these pharmacodynamic properties, tofisopam has been considered as an atypical BZD [178; 183]. Tofisopam is rapidly absorbed from the intestinal tract, peak plasma concentrations are reached within 1-1.5 hours in humans [189]. After oral absorption, it undergoes extensive first-pass hepatic metabolism, mainly by demethylation, and has a t ½ of around 6-8 hours [190]. Hatayama et al. [191] described an hypouricemic effect after 2-3 hours following oral administration of tofisopam (300 mg daily) comparable or greater than that of losartan and/or fenofibrate; hence, it may be suggested in patients with hyperuricemia and/or gout with concomitant autonomic dysfunction symptoms. **There are no further data about clinical, pharmacological or toxicological properties. Tofisopam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Tofisopam was firstly identified in 80 white tablets, labelled as 'GRANDAX', seized in blister packs by Swedish Customs in Malmö on 22 November 2017. The substance was analytically confirmed using GC-MS, NMR and LC-HRMS by the Swedish National Forensic Centre [11]. There is considerable information available on the pharmacology, toxicology and clinical profile of this substance, as there are some published reports on tofisopam, particularly focusing on its anxiolytic properties and alleviating effects on gastrointestinal functional or psychosomatic disorders [177; 182; 185-188; 192-194]. A Japanese retrospective observational study carried out on a sample of patients affected with functional dyspepsia described a significant improvement ($p<.05$) at the Gastrointestinal Symptom Rating Scale (GSRS) total score, the State-Trait Anxiety Inventory (STAY) total score, and the Zung Self-rating Depression Scale (SDS) total score, and at the following GSRS domains: abdominal pain, indigestion and constipation [177]. A case-report described a clinically significant efficacy of tofisopam in the treatment of paroxysmal supraventricular tachycardia [194]. There are significant anecdotal reports on psychonaut fora which describe a "*relaxing effect*" with "*excellent concentration, motivation and sociability, without any muscle relaxant or any sedative or amnestic properties and without any apparent withdrawal effects*" [51; 116].

3.27. Flualprazolam

Flualprazolam is a 1,2,4-triazolobenzodiazepine, where the diazepine ring is fused to a triazole ring. Flualprazolam is the 2-fluoro derivative of alprazolam and it differs from triazolam by replacement of the chlorine with fluorine at the 2-position (*ortho* position) on the phenyl ring attached to the benzodiazepine moiety. Both substances, alprazolam and triazolam, are under international control. Flualprazolam is also structurally related to flubromazolam, formally notified to the EMCDDA in 2014 [152], from which it differs due to the replacement of bromine with chlorine at the 8-position on the benzodiazepine moiety [96; 195]. The synthesis of flualprazolam has been previously described [96; 195-196]. Based on its chemical structure and similarity to alprazolam and triazolam the substance is expected to have sedative and hypnotic effects. The 1,4-triazolo ring present in triazolobenzodiazepines prevents the oxidative metabolism of classical BZDs (i.e., diazepam), which results in formation of active metabolites with long elimination t ½ [197]. In some of the pharmacological tests conducted on mice, fluaprazolam was reported to be active at doses of less than 10 μg/kg [96]. **There are no further data about clinical, pharmacological or toxicological properties. Flualprazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Flualprazolam was first identified in 89.8 grams of pale beige powder seized by Swedish police in Linköping on 29 November 2017. The substance was analytically confirmed using GC-MS, LC-HRMS and NMR by the Swedish

National Forensic Centre [11]. It was also identified in 1 gram of yellow powder, collected by the Slovenian National Forensic Laboratory in Ljubljana, purchased from the Internet, as part of the RESPONSE 2 project and was received on 3 January 2018. The price was 129 US dollars per 1 gram and the sample was advertised as flualprazolam. The substance was analytically confirmed using GC-MS, HPLC-TOF, IC, FTIR-ATR, GC-(MS)-IR condensed phase at the Slovenian National Forensic Laboratory and by NMR at the Faculty of Chemistry and Chemical technology, University of Ljubljana [10]. There is limited information available on the pharmacology and toxicology of this substance, as there are not published reports so far. However, in a recent report by WHO ECDD on flualprazolam, more than 25 deaths with confirmed exposure to flualprazolam and around 30 non-fatal poisonings with suspected exposure have been reported so far [12]. The presence of this molecule in material seized in relation to an 'anesthesia robbery' case has recently been reported [198]. There are limited clinically significant anecdotal reports from psychonaut fora. A longer half-life and higher potency compared to alprazolam is reported, with strong and heavy effects after oral intake of 0.5-1 mg and 1-2 mg respectively [58]. Symptomatology occurs 10-30 minutes after oral intake, effects may last 6-14 hours and after-effects for 36 hours [58]. Flualprazolam appears to be marketed as 'fake' alprazolam (labelled as 'Xanax®' or Xanor' tablets) and some psychonauts defined it as the "*king of the RC benzos*" (i.e. the king of the research chemicals benzodiazepines) [54; 199-200].

3.28. Clobromazolam/Phenazolam

Clobromazolam is a 1,2,4-triazolobenzodiazepine, where the diazepine ring is fused to a triazole ring. Clobromazolam is the 2-chloro derivative of bromazolam and shares structural similarities with clonazolam and flubromazolam, formally notified to the EMCDDA in 2016, 2015 and 2014 respectively [152]. Clobromazolam is structurally related to the internationally controlled substances phenazepam, alprazolam and triazolam. The synthesis of clobromazolam (compound V) has been previously described in the literature; it differs from triazolam due to replacement of chlorine with bromine at the 8-position on the **benzodiazepine moiety** [201]. It has been pharmacologically evaluated following oral administration in mice and reported as "*very potent in pharmacological tests for anticonvulsant, central depressant and discoordination activity in mice*", with strong central depression, ataxia and convulsive reactions at doses of 0**.2-1 g/kg**, with symptoms lasting more than 24 hours [201]. The acute toxicity of clobromazolam was found to be very low in mice and, compared to triazolam, it has a similarly low toxicity with a similar anticonvulsant effect towards pentetrazol, with 25% of the triazolam activity in the test of electroshock, 12% of the locomotor inhibiting effect and 40% of the discoordination activity [201]. **There are no further data about clinical, pharmacological or toxicological properties. Clobromazolam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Clobromazolam was first identified in 20 white capsules containing white powder seized by Swedish Police in Luleå on 11 March 2016 [11]. The substance was analytically confirmed using GC-MS, LC-HRMS and NMR by the Swedish National Forensic Centre [11]. There is limited information available on the pharmacology and toxicology of this substance, as there are no published reports so far. There are no clinically significant anecdotal reports from psychonaut fora describing clinical effects of clobromazolam so far.

3.29. Bentazepam

Bentazepam is a thienodiazepine which differs from the previous notified thienodiazepines (i.e., etizolam, metizolam and fluclotizolam) due to the presence of a cyclohexane fused to the thiophene instead of a triazole [201]. Bentazepam was used in the manufacture of a medicinal product for human use authorized in Spain and marketed as

Tiadipona® (marketing authorization suspended on 6 March 2019) [202]. It exerts anxiolytic, anticonvulsant, sedative and muscle relaxant effects [203-204]. Its peak plasma concentration is reached within 1-3 hours after oral administration and it has a t ½ of approximately 3.3 hours [202]. Hepatitis and severe liver damage have also been associated with bentazepam [205-209]. **There are no further data about clinical, pharmacological or toxicological properties. Bentazepam is not currently controlled under the 1971 United Nations Convention on Psychotropic Substances or the 1961 Single Convention on Narcotic Drugs**.

Bentazepam was firstly seized by the Swedish Police, on 3 March 2014, in Borlänge in a sample of 6 white round tablets. The substance was identified by the Swedish National Forensic Centre sing GC-MS and reference material [110]. There are limited clinically significant anecdotal reports from psychonaut fora. A low dose is 15-30 mg, a typical dose is 30-50 mg whilst a strong effect is experienced with 50-75 mg or more [58]. Symptomatology happens 15-45 minutes after oral intake, effects may last 3-6 hours and after-effects for 1-8 hours after administration [58].

4. Discussion

During recent years, the advent of NPS and the dissemination of internet purchasing has meant that some BZDs, that are not licensed in most countries, but which remain available in some others (i.e., Russia and ex-Soviet Union states), began to appear more widely and frequently in the NPS market as '*legal and without medical prescription alternative'* to the common regulated pharmaceutical BZDs (i.e., phenazepam, etizolam, etc.). However, beside these BZDs, there are also completely new and recently synthetised NPS BZDs (i.e., pyrazolam, flubromazepam, etc.), some of them were previously research trial compounds whose development did not proceed to clinical use [79; 210]. These compounds are sold as tablets, powder, pellets, capsules or blotters, and recently liquids under their own names, at very affordable prices [37; 211-212]. **They are usually administered orally, intramuscularly, intravenously or insufflated nasally, or inhaled by smoking or vaporisation; occasionally rectally** [70; 152; 211]. Most designer BZDs possess a liver metabolism, primarily by oxidative metabolism mediated by the CYP450 family, mainly CYP3A4 [152]. One of the major issues and concerns related to the emergence of NPS BZDs is that there is no guarantee of the quality of their composition and purification and, hence, most NPS consumers may be inadvertently taking not that BZD labelled but another compound (belonging or not to the BZD family) and potentially many times more harmful than expected, due to the lack of information regarding drug-drug interactions. In fact, some of them are also sold on the illicit drug market as counterfeit forms of other traditional/pharmaceutical BZDs (e.g., diazepam, alprazolam, etc.), which may increase the risk of unintentional overdose and intoxication [9-10; 170]. Furthermore, there have been sporadic reports of the use of these designer BZDs as either adulterants or diluents in heroin or other synthetic opioids or cannabinoids, with consequent respiratory depression documented [8; 213-214].

Designer BZDs began to appear as recreational drugs/NPS around 2007 [68; 152; 215]. Between 2012 and 2019, new compounds classified as 'designer BZDs' started to be distributed by online retailers, mostly labelled as 'research chemicals' [10]. Some of these compounds are extremely powerful, also at lower dosages (i.e., flubromazolam) [152; 215]. **Indeed, psychonauts boosted the NPS market and shaped the drug market overall, by increasing NPS, including designer BZDs, popularity and interest by posting technical and accurately descriptive trip reports on the web. In fact,** the increasing interest towards the 'psychonauts' world', and contextually towards online platforms, specifically designed and disseminated as "pro-drug" virtual informative centers for e-psychonauts, facilitated the exchange of pharmaceutical and clinical 'dirty' (aka 'unsafe', 'unverified') information about NPS in general, and, specifically, on designer BZDs [216-218]. However, there is currently a "dramatic gap" in the information flow amongst clinicians working in the Addiction and/or in Mental Health services, as this gap is represented by the information

available on the surface (i.e., mainly derived by the information provided by EMCDDA/other drug monitoring systems and literature) and those 'hidden' (i.e., accessible mainly amongst NPS consumers, as shared/posted by themselves; hence, mainly available online but not always 'verified'). Moreover, it is assumed that clinicians working in Mental Health and **Addiction Services may "underestimate" the real number of designer BZDs consumers and, hence, they may not collect clinically relevant data on their clinical, pharmacological and toxicological effects. This consideration mainly derived by the fact that there are not so far published epidemiological data on this relatively new emerging phenomenon, as it may be difficult to collect data for several reasons here listed: a) most designer BZDs are extremely new and unknown by clinicians who do not ask for that specific compound to their patients; b) most consumers (mainly those who buy drugs/NPS, including designer BZDs online) may not completely aware if they are taking traditional or designer BZDs which are frequently sold as counterfeit of traditional BZDs; c) most NPS consumers may not completely aware if they are taking designer BZDs as they are mainly contained as adulterants, etc. in NPS packages without specifying they are mixed with synthetic opioids/cannabinoids, etc.**

Overall, the effects of designer BZDs largely vary depending on the dose(s) consumed, the route of administration and combination with other drugs/medicaments/substances. However, information on the effects of these designer BZDs are largely limited to self-reported experiences coming from online trip reports and limited case-reports and/or case-series [37; 152; 170; 216]. By analogy to traditional BZDs, the desired effects may include sociability, muscle relaxation, sleep-inducing and anxiolytic effects, as reducer of chronic pain, and nervousness. At lower doses, BZDs may cause drowsiness, fatigue and lethargy; whilst, at higher doses motor coordination disorders, mood swings, dizziness and sometimes euphoria have been reported [152]. The use of BZDs, including 'designer benzos' varies from country to country, even within the UK. So, whilst 'traditional' BZDs account for most of BZD-related fatalities in Northern Ireland, in Scotland it is NPS varieties that dominate not only the BZD-related poisoning deaths, but all drug-poisoning related ones. For example, nearly 95% of all NPS-related deaths registered in Scotland during the period 2013-8 involved BZD analogues (unpublished data from National Records of Scotland). **Furthermore, dependence and tolerance have been documented as well as withdrawal syndrome after abrupt discontinuation [150; 152; 219]. In fact, designer BZDs, like traditional ones, play an integral role in the reinforcing and addictive properties through the $GABA_A$ receptors in the mesolimbic dopaminergic pathway, by determining the onset of a tolerance and a physical and psychological dependence [219].**

Limitations of the present study

Therefore, the great limitation of the present overview arises from the fact that the information search strategy has been mainly performed on those designer BZDs so far notified to EMCDDA and not strictly limited to all designer BZDs currently available on the NPS market. The ongoing 'NPS finder' project performed by our research team is working to develop a useful online tool able to identify a much larger number of NPS, including BZDs, by specifically focussing on psychonauts' entries only. Therefore, one of the major limitation of our work is directly related to these 'information' and 'search strategy' biases which indeed limit the reliability of the findings collected here. In addition, most data here discussed mainly derive from cases of intoxications (i.e., subjects coming to the emergence departments due to health risky reactions following designer BDZs intake) or trip experiences collected through a netnographic approach on the web.

5. Conclusions

BZDs are a class of drugs widely prescribed for the short-term treatment of anxiety, epilepsy, muscle spasm, alcohol withdrawal and insomnia. However, BZDs can also be misused and/or abused by various substance user groups, mainly in combination with other drugs of abuse (e.g., opioids, psychostimulants, etc.) [152; 215]. Their wide application and use facilitates the diffusion and growth of an extensive interest in research around their chemical structures, pharmacological properties and clinical effects, by incentivising the development of a wide variety of active compounds that did not obtain marketing authorisation and which are now being rediscovered and sold online as 'legal alternatives to the prescribed-only BZDs', becoming indeed NPS (aka 'designer/synthetic/new BZDs') [10]. **Despite limited information so far available for most of these 'designer BZDs', a recent trend in the NPS market appears to be a greater diffusion of this class [10]. One could argue that a possible explanation may depend on country, i.e. in some countries such as the UK it is indeed extremely difficult to be prescribed with BZDs; other explanations could be that this dramatic increased trend is related to higher rates of anxiety disorders, particularly amongst substances users, and an increased number of subjects who self-medicate [220]. Furthermore, designer BZDs may represent a target of interest as well for those subjects who commonly abuse other substances (i.e., opioids, psychostimulants, etc.). The recent increase in the dissemination and seizures of this new NPS class, observed during the last several years, poses a great concern regarding health risks associated with their intake, particularly amongst those vulnerable subjects who consume other substances [211; 221]. In fact, combining designer BZDs with other drugs (e.g., ethanol, marijuana, stimulants, opioids, and other psychoactive substances) can prove to be risky, especially as there are no reliable data about any possible synergic and antagonistic effects.**

Therefore, further clinical research should be conducted within this field in order to better identify and prevent potential risky behaviours and attenuate (if not actually eliminate) health risks associated with the intake of these designer/synthetic/new BZDs. A preventive and informative campaign should be aimed at clinicians and mental health professionals as well as amongst drug users about this new class of BZDs.

References

[1] Stahl, S. Stahl's Essential Psychopharmacology: Neuroscientific Basis & Practical Applications. 4rd ed. Cambridge University Press, 2013.

[2] Tan, K.R.; Rudolph, U.; Lüscher, C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. *Trends Neurosci.* 2011, 34 (4), 188–197. Doi: 10.1016/ j.tins.2011.01.004.

[3] Bellantuono, C.; Balestrieri, M. Psicofarmacoterapia. In: *Balestrieri M., Bellantuono C, Berardi D, Di Giannantonio M, Rigatelli M, Siracusano A, Zoccali RA (Eds.).* 2nd ed. Il Pensiero Scientifico Editore, Roma, 2014.

[4] Greenblatt, H.K.; Greenblatt, D.J. Designer Benzodiazepines: A Review of Published Data and Public Health Significance. *Clin Pharmacol Drug Dev.*, 2019, Apr;8(3), 266-269. Doi: 10.1002/cpdd.667.

[5] Fukasawa, T.; Suzuki, A.; Otani, K. Effects of Genetic Polymorphism of Cytochrome P450 Enzymes on the Pharmacokinetics of Benzodiazepines. *J Clin Pharm Therap,* 2007, 32, 333-341.

[6] Dear, J.W.; Bateman, D.N. Benzodiazepines. *Medicine*., 2016, 44, 145.

[7] Moosmann, B.; Bisel, P.; Auwärter, V. Characterization of the designer benzodiazepine diclazepam and preliminary data on its metabolism and pharmacokinetics. *Drug Test Anal.*, **2014,** Jul-Aug;6(7-8), 757-763. Doi: 10.1002/dta.1628.

[8] Moosmann, B.; King, L.A.; Auwärter, V. Designer benzodiazepines: A new challenge. *World Psychiatry*. **2015,** Jun;14(2), 248. Doi: 10.1002/wps.20236.

[9] United Nations Office on Drugs and Crimes (UNODC). Global SMART Update Volume 18, Non-medical use of benzodiazepines: a growing threat to public health? (2019). Https://www.unodc.org/documents/scientific/Global_SMART_Update_2017_Vol_18.pdf (Accessed Oct 6, 2019).

[10] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2019: Trends and Developments (2019). Publications Office of the European Union, Luxembourg. Http://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF.pdf (Accessed Oct 6, 2019).

[11] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The misuse of benzodiazepines among high-risk opioid users in Europe (2015). Publications Office of the European Union, Luxembourg. Http://www.emcdda.europa.eu/system/files/publications/2733/Misuse%20of%20benzos_POD2015.pdf (Accessed Oct 6, 2019).

[12] World Health Organization (WHO). Critical Revie Report: flualprazolam. Expert Committee on Drug Dependence Forty-Second Meeting. Geneva, 21-25 October 2019. Https://www.who.int/medicines/access/controlled-substances/Final_Flualprazolam.pdf?ua=1 (Accessed Oct 15, 2019).

[13] Darbinian, T.M.; Papin, A.A.; Vagina, M.A.; Petrov, O.V. Comparative study of the sedative and tranquilizing effect of phenazepama and seduxen and their influence on human evoked brain potentials. *Farmakologiia Toksikologiia.*, 1979, 42, 592-597.

[14] Zakusov, V.V. New psychotropic phenazepam preparation. *Pharm Chem J (Ussr).*, **1979**, 13, 1094-1097.

[15] Sozinov, V.A.; Rudenko, O.P.; Zinkovskii, V.G.; Golovenko, N.Y.; Lisitsyna, A.L. Synthesis of hydrogenated analog of phenazepam. *Pharm Chem J (Ussr).*, **1984**, 18, 721-725.

[16] Rafstedt, K.; Hultén, P.; Brusiu, K. Phenazepam as a drug of abuse-high frequency of prolonged symptoms. *Clin Toxicol.*, **2009**, 47, 436-510.

[17] Johnson, W. Phenazepam in Wisconsin drivers. In: Annual meeting of the Society of Forensic Toxicologist. 2010; Richmond, Virginia, USA.

[18] Baselt, R.C. *Disposition of toxic drugs and chemicals in man*, 5th Ed.; Seal Beach, California: Biomedical Publications; **2011**, 1320-1321.

[19] Maskell, P.D.; Paoli, G.D.; Seetohul, L.N.; Pounder, D.J. Phenazepam is currently being misused in the UK. *BMJ*, **2011,** 343, d4207.

[20] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Country Overview: Moldova (2009). Publications Office of the European Union, Luxembourg. Http://www.emcdda.europa.eu/publications/country-overviews/md (Accessed Oct 6, 2019).

[21] European Monitoring Centre for Drugs and Drug Addiction. European Legal Database on Drugs (2011). Publications Office of the European Union, Luxembourg. http:// www.emcdda.europa.eu/eldd (Accessed Oct 6, 2019).

[22] Drugs-Forum. Legal status of phenazepam around the world (2019). Https://drugs-forum.com/forum/showwiki.php?title1⁄4Phenazepam (Accessed Oct 6, 2019).

[23] Advisory Council on the Misuse of Drugs (ACMD). Phenazepam advice. Letter from chair of ACMD to Minister of State for Crime Prevention and ASB reduction (2011). Http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/acmd- advice-phenazepam?view=Binary (Accessed Oct 6, 2019).

[24] Home Office (2011). Import ban of new 'legal high' phenazepam introduced. Home Office, London. Https://www.gov.uk/government/news/import-ban-of-new-legal- high-phenazepam-introduced (Accessed Oct 6, 2019).

[25] Home Office (2012). Circular: a change to the Misuse of Drugs Act 1971. Home Office circular 014/2012 A Change to the Misuse of Drugs Act 1971: control of pipradrol-related compounds and phenazepam. Https://www.gov.uk/government/publications/a-change-to-the-misuse-of-drugs-act-1971- control-of-pipradrol-related-compounds-and-phenazepam (Accessed Oct 6, 2019).

[26] Lillsunde, P.; Gunnar, T. Drugs and driving: the Finnish perspective. *Bull Narc.*, **2005**, 57 (1 and 2), 213-219.

[27] Gjerde, H.; Christophersen, A.S.; Normann, P.T.; Morland, J. Toxicological investigations of drivers killed in road traffic accidents in Norway during 2006-2008. *Forensic Sci Int.*, **2011,** 212 (1-3), 102-109.

[28] Kriikku, P.; Wilhelm, L.; Rintatalo, J.; Hurme, J.; Kramer, J.; Ojanperä, I. Phenazepam abuse in Finland: findings from apprehended drivers, post-mortem cases and police confiscations. *Forensic Sci Int.*, **2012**, Jul 10, 220(1-3), 111-117. Doi:10.1016/j.forsciint.2012.02.006.

[29] Zherdev, V.P.; Caccia, S.; Garattini, S.; Ekonomov, A.L. Species differences in phenazepam kinetics and metabolism. *Eur J Drug Metab Pharmacokinet*., **1982**, 7(3), 191-196.

[30] Mykkanen, S.; Gunnar, T.; Ariniem, K.; Lillsunde, P.; Krasnova, R. Quantitation of phenazepam in blood by GC-eMS in positive drug-driving cases in Finland. In: The annual meeting of the Society of Forensic Toxicologists, **2004**, Washington DC, USA.

[31] Mrozkowska, J.; Vinge, E., Boma, C. Missbruk av fenazepam - ny företeelse i Sverige [Abuse of phenazepam - new phenomenon in Sweden]. *Larkartidningen.*, **2009**, 106, 516-517.

[32] Bailey, K.; Richards-Waugh, L.; Clay, D.; Gebhardt, M.; Mahmoud, H.; Kraner, J.C. Fatality involving the ingestion of phenazepam and poppy seed tea. *J Anal Toxicol*., **2010**, 34(8), 527-532.

[33] Volgram, J.; Khdasevitsch, T. A fatal case due to phenazepam. *Bull Int Assoc Forensic Toxicologists*., **1999**, 29(4), 13.

[34] Boone, C. Exotic drug leaves Cherokee teen dead, 3 friends hospitalized. (2010). *Cherokee County News* (20 September 2010). Http://www.ajc.com/news/news/local/exotic-drug-leaves-cherokee-teen-dead-3-friends- ho/nQkNR/ (Accessed Oct 6, 2019).

[35] Corkery, J.M.; Schifano, F.; Ghodse, H. UK fatality involving phenazepam. *BMJ.*, **2011**, 343, d4207.

[36] Yip, T.; Martin, A.; Scott, K.S. Phenazepam abuse in the West of Scotland 2009-2011. In: UKIAFT Annual Meeting. **2011**; Aberdeen, Scotland.

[37] Corkery, J.M.; Schifano, F.; Ghodse, A.H. Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death. *Hum. Psychopharmacol.,* **2012,** 27 (3), 254–261. Doi: 10.1002/hup.2222.

[38] Corkery, J.; Claridge, H.; Loi, B.; Goodair, C.; Schifano, F. Drug-related deaths in the UK: January-December 2012. Annual Report 2013, National Programme on Substance Abuse Deaths (NPSAD). (2013). St George's, University of London. Http://www.sgul.ac.uk/research/population-health/our-projects/national-programme-on- substance-abuse-deaths (Accessed Oct 6, 2019).

[39] Dargan, P.I.; Davies, S.; Puchnarewicz, M.; Johnston, A.; Wood, D.M. First reported case in the UK of acute prolonged neuropsychiatric toxicity associated with analytically confirmed recreational use of phenazepam. *Eur J Clin Pharmacol*., **2013**, 69(3), 361-363.

[40] National Records of Scotland. (2014). Drug-related deaths in Scotland in 2013. http://www.gro-scotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2013 (Accessed Oct 6, 2019).

[41] Barnsdale L, Gordon R, McAuley A. The National Drug-Related Deaths Database (Scotland) Report: Analysis of deaths occurringin 2013. (2015). Http://www.isdscotland.org/Health-Topics/Drugs-and-Alcohol-Misuse/Publications/2015- 04-28/2015-04-28-NDRDD-Report.pdf (Accessed Oct 6, 2019).

[42] McAuley, A.; Hecht, G.; Barnsdale, L.; Thomson, C.S.; Graham, L.; Priyadarshi, S., Robertson, J.R. Mortality related to novel psychoactive substances in Scotland, 2012: an exploratory study. *Int J Drug Policy*. **2015**, 26(5), 461-467.

[43] Shearer, K.; Bryce, C.; Parsons, M.; Torrance, H. Phenazepam: A review of medico-legal deaths in South Scotland between 2010 and 2014. *Forensic Sci Int*. **2015**, 254, 197-204.

[44] Luzhnikov, E.A.; Sukhodolova, G.N.; Ostapenko, Y.N.; Kovalenko, L.A.; Dolginov, D.M. Clinical toxicometry of acute poisonings by fenazepam in older children. *Clin Toxicol*., **2010**, 48, 282.

[45] Aleksandrovskiy, Y.A.; Kraznov, V.N.; Neznanov, L.V.; Romasenko, L.V. Efficacy of etifoxine versus phenazepam in treatment of patients with adjustment disorders (open-label randomized controlled trial). *Russian J Psychiatry.*, **2010**, 1, 74-8.

[46] Ali, A.; Jerry, J.M.; Khawam, E.A. Delirium induced by a new synthetic legal intoxicating drug: phenazepam. *Psychosomatics.*, **2015**, 56(4), 414-418.

[47] Bogatskii, A.V.; Golovenko, Y.; Zinkovskii, V.G. Intrahepatic circulation of 14C-phenazepam and its metabolites in albino rats. *Bull Exp Biol Med*., **1980,** 89(1), 32-35.

[48] Kopanitsa M.V.; Zbarska, S.M.; Boychuk, Y.; Krishtal, O.A. Modulation of GABA-activated currents by phenazepam and its metabolites in isolated rat Purkinje neurons. *Neurophysiology.*, **2000**, 32(3), 192.

[49] Dorofeyeva, O.A.; Syunyakov, S.A.; Neznamov, G.G. Comparative analysis of different phenazepam formulations. In: Regional congress of the World Psychiatric Association. Petersburg, **2010**, 83.

[50] Maskell, P.D.; De, P.G.; Nitin, S.L.; Pounder, D.J. Phenazepam: the drug that came in from the cold. *J Forensic Leg Med.*, **2012**, 19(3), 122-125.

[51] Bluelight.org. Https://www.bluelight.org (Accessed Oct 6, 2019).

[52] Erowid.org. Https://www.erowid.org (Accessed Oct 6, 2019).

[53] Golovenko, N.Y.; Kravchenko, I.A.; Zin'kovskii, V.G.; Andronati, S.A.; Aleksandrova, A.I.; Ovcharenko, N.V.; Larionov, V.B. Biokinetics of transdermal therapeutic medicinal form of phenazepam. *Bull Exp Biol Med*., **2000**, 130(12), 1153-115.

[54] Drugs-Forum.com. Https://drugs-forum.com (Accessed Oct 6, 2019).

[55] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA–Europol 2007. Annual Report on the Implementation of Council Decision 2005/387/JHA, 2007. Lisbon, Portugal, Http://www.emcdda.europa.eu/system/files/publications/503/2007_Implementation_report_281403.pdf. (Accessed Oct 6, 2019).

[56] Couch, R.A.; Madhavaram, H. Phenazepam and cannabinomimetics sold as herbal highs in New Zealand. *Drug Test Anal.*, **2012,** Jun;4(6), 409-414.

[57] Lee, C.; Lee, H.; Pyo, J.; Jo, J.; Lee, J.; Choi, H., Kim, S.; Seon, R.; Yonghoon, H.; Bang, P.; Hwang, H.; Choe, S.; Jung, J.H. Identification of a new synthetic cannabinoid in a herbal mixture: 1-butyl-3-(2-methoxybenzoyl)indole. *Forensic Toxicol.*, **2013**, 31(2), 187-196.

[58] Tripsit. Http://drugs.tripsit.me/ (Accessed Oct 6, 2019).

[59] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA–Europol 2011. Annual Report on the Implementation of Council Decision 2005/387/JHA, 2011. Lisbon, Portugal, Http://www.emcdda.europa.eu/system/files/publications/689/EMCDDA-Europol_Annual_Report_2011_2012_final_335568.pdf. (Accessed Oct 6, 2019).

[60] Fracasso, C.; Confalonieri, S.; Garattini, S.; Caccia, S. Single and multiple dose pharmacokinetics of etizolam in healthy subjects. *Eur J Clin Pharmacol.* **1991**;40(2), 181-185.

[61] Nakamae, T.; Shinozuka, T.; Sasaki, C.; Ogamo, A.; Murakami-Hashimoto, C.; Irie, W.; Terada, M.; Nakamura, S.; Furukawa, M.; Kurihara, K. Case report: Etizolam and its major metabolites in two unnatural death cases. *Forensic Sci Int.*, **2008** Nov 20; 182(1-3), e1-6. Doi: 10.1016/j.forsciint.2008.08.012.

[62] National Records of Scotland (2019). Table SUB2 - Substances which were reported for drug-related deaths on the basis of the Office for National Statistics (ONS) 'wide' definition, Scotland, 2000 to 2018. 16 July, Edinburgh: National Records of Scotland. Available at: https://www.nrscotland.gov.uk/files//statistics/drug-related-deaths/2018/drug-related-deaths-sub2-18.xlsx (Accessed 6 October 2019).

[63] Moosmann, B.; Hutter, M.; Huppertz, L.M.; Ferlaino, S.; Redlingshöfer, L.; Auwärter, V. Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine. *Forensic Toxicol.*, **2013**, 31(2), 263-271.

[64] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol 2012. Annual Report on the Implementation of Council Decision 2005/387/JHA, 2012. Lisbon, Portugal, Http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf. (Accessed Oct 6, 2019).

[65] Sternbach, L.H.; Fryer, R.Y.; Metlesics, W.; Reeder, E.; Sach, G.; Saucy, G.; Stempel, G. Quinazolines and 1,4-Benzodiazepines. VI.1a Halo-, Methyl-, and Methoxy-substituted 1,3-Dihydro-5-phenyl-2H-1,4- benzodiazepin-2-ones1b,c. *J. Org. Chem.*, **1962**, 27, 3788.

[66] Carter, M. C.; Alber, D. G.; Baxter, R.C.; Bithell, S.K.; Budworth, J.; Chubb, A.; Cockerill, G.S.; Dowdell, V.C.L.; Henderson, E.A.; Keegan, S.J.; Kelsey, R.D.; Lockyer, M.J.; Stables, J.N.; Wilson, L.J.; Powell, K.L. 1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. *J. Med. Chem.*, **2006**, 49, 2311–2319.

[67] Koch, K.; Auwärter, V.; Hermanns-Clausen, M.; Wilde, M.; Neukamm, M.A. Mixed intoxication by the synthetic opioid U-47700 and the benzodiazepine flubromazepam with lethal outcome: Pharmacokinetic data. *Drug Test Anal.*, **2018** Apr 10. Doi: 10.1002/dta.2391.

[68] Petterson Bergstrand, M.; Helander, A.; Hansson, T.; Beck, O. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. *Drug Test Anal.*, **2017** Apr;9(4), 640-645. Doi: 10.1002/dta.2003.

[69] Bäckberg, M.; Petterson Bergstrand, M.; Beck, O.; Helander, A. Occurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project. *Clin Toxicol (Phila).*, **2019** Mar;57(3), 203-212. Doi:10.1080/15563650.2018.1506130.

[70] Carpenter, J.E.; Murray, B.P.; Dunkley, C.; Kazzi, Z.N.; Gittinger, M.H. Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017. *Clin Toxicol (Phila).*, **2019** Apr;57(4), 282-286. Doi: 10.1080/15563650.2018.1510502.

[71] Ligon, E.S.; Nawyn, J.; Jones, L.V.; Allred, B.M.; Reinhardt, D.V.; France, S. Synthesis of Flubromazepam Positional Isomers for Forensic Analysis. *J Org Chem.*, **2019,** Jul 20. Doi: 10.1021/acs.joc.9b01433.

[72] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2013. Annual Report on the Implementation of Council Decision 2005/387/JHA, 2013. Lisbon, Portugal. Http://www.emcdda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf. (Accessed Oct 6, 2019).

[73] Manchester, K.R.; Maskell, P.D.; Waters, L. Experimental versus theoretical log D(7.4) , pK(a) and plasma protein binding values for benzodiazepines appearing as new psychoactive substances. *Drug Test Anal.*, **2018** Mar 26. Doi: 10.1002/dta.2387.

[74] Sternbach, L.H.; Fryer, R.I.; Metlesics, W.; Sach, G.; Stempel, A. Quinazolines and 1,4-Benzodiazepines. V. o-Aminobenzophenones, *J. Org. Chem*., **1962**, 27 (11), 3781–3788.

[75] Babbini, M.; Gaiardi, M.; Bartoletti, M. Anxiolytic versus sedative properties in the benzodiazepines series: Differencies in structure -activity relationships. *Life Sci.*, **1979**, 25, 15.

[76] Sternbach, L.H.; Randall, L.O.; Banziger, R.; Lehr, H. Structure-activity relationships in the 1,3-benzodiazepine series. In: *Drugs Affecting the Central Nervous System*, Ed: A. Burger, Edward Arnold, London, **1968**.

[77] Bradley, C.M.; Nicholson, A.N. Activity of the chloro- and triazolobenzodiazepines: Behavioural studies in the monkey (Macaca mulatta). *Neuropharmacology.*, **1984**, 23, 327.

[78] Cho, M.J.; Sethy, V.H.; Haynes, L.C. Sequentially labile water-soluble prodrugs of alprazolam. *J. Medicinal Chem.*, **1986**, 29(8), 1346-1350.

[79] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2014. Annual Report on the Implementation of Council Decision 2005/387/JHA, 2014. Lisbon, Portugal. Http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed Oct 6, 2019).

[80] Thibault, J.P.; Monteiro, L.M.; Leite, L.C; Menezes, C.M.; Lima, L.M.; Noël F. 'The effects of 3-methylclonazepam on Schistoma mansoni musculature are not mediated by benzodiazpeine receptors'. *Eur J Pharmacol.*, **20**09, 606 (1-3), 9-16.

[81] Vikingsson, S.; Wohlfarth, A.; Andersson, M.; Gréen, H.; Roman, M.; Josefsson, M.; Kugelberg, F.C., Kronstrand, R. Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. *AAPS J.*, **2017** May;19(3), 736-742. Doi: 10.1208/s12248-016-0040-x.

[82] Baard, A.P.; Sommers, D.K.; Honiball, P.J.; Fourie, E.D.; du Toit, LE. Preliminary results in human schistosomiasis with Ro 11-3128. *S Afr Med J.*, **1979,** 55(16), 617–618.

[83] Ansseau, M.; Doumont, A.; Thiry, D.; von Frenckell, R.; Collard, J. Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. *Psychopharmacology (Berl).*, **1985**, 87(2), 130-135.

[84] Abdul-Ghani RA, Loutfy N, Hassan A. Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. *Parasitol Res*., **2009;**105(4), 899–906. Doi:10.1007/s00436-009-1546-2.

[85] O'Boyle, C.; Lambe, R.; Darragh, A. Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam. *Eur J Clin Pharmacol.*, **1985**, 29(1), 105–108.

[86] Coassolo, P.; Aubert, C.; Cano, J.P. Plasma determination of 3-methylclonazepam by capillary gas chromatography. *J Chromatogr.*, **1985,** 338(2), 347–355.

[87] Ameline, A.; Richeval, C.; Gaulier, J.M.; Raul, J.S.; Kintz, P. Characterization of Flunitrazolam, a New Designer Benzodiazepine, in Oral Fluid After a Controlled Single Administration. *J Anal Toxicol.*, **2018,** Jul 1;42(6), e58-e60. Doi: 10.1093/jat/bky012.

[88] Huppertz, L.M.; Bisel, P.; Westphal, F.; Franz, F.; Auwärter, V.; Moosmann, B. Characterization of the four designer benzodiazepines clonazolam, deschloroetizolam, flubromazolam, and meclonazepam, and identification of their in vitro metabolites. *Forensic Toxicol.*, **2015**, 33, 388-395.

[89] Abe, M.; Mikashima, H.; Moriwaki, M.; Tahara, T. Thieno(-triazolo)diazepine compound and medicinal application of the same (1988). Patent WO1988009333A1.

[90] Huppertz, L.M.; Moosmann, B.; Auwärter, V. Flubromazolam - Basic pharmacokinetic evaluation of a highly potent designer benzodiazepine. *Drug Test Anal.*, **2018**, Jan;10(1), 206-211. Doi: 10.1002/dta.2203.

[91] Noble, C.; Mardal, M.; Bjerre Holm, N.; Stybe Johansen, S.; Linnet, K. In vitro studies on flubromazolam metabolism and detection of its metabolites in authentic forensic samples. *Drug Test Anal.*, **2017**, Aug;9(8), 1182-1191. Doi: 10.1002/dta.2146.

[92] Wohlfarth, A.; Vikingsson, S.; Roman, M.; Andersson, M.; Kugelberg, F.C.; Green, H.; Kronstrand, R. Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. *Forensic Sci Int.*, **2017** May; 274, 55-63. Doi: 10.1016/j.forsciint.2016.10.021.

[93] Bohnenberger, K.; Liu, M.T. Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil. *Ment Health Clin*., **2019,** May 10;9(3), 133-137. Doi: 10.9740/mhc.2019.05.133.

[94] Łukasik-Głębocka, M.; Sommerfeld, K.; Teżyk, A.; Zielińska-Psuja, B.; Panieński, P.; Żaba, C. Flubromazolam--A new life-threatening designer benzodiazepine. *Clin. Toxicol. (Phila).*, **2016**, 54(1):66-8. Doi: 10.3109/15563650.2015.1112907.

[95] Katselou, M.; Papoutsis, I.; Nikolaou, P.; Spiliopoulou, C.; Athanaselis, S. Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam. *Forensic Toxicol*., **2017**, 35(1), 1-10. Doi: 10.1007/s11419-016-0338-5.

[96] Hester, J.B. Jr.; Rudzik, A.D.; Kamdar, B.V. 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines which have central nervous system depressant activity. *J Med Chem*., **1971**, 14, 1078-1081.

[97] Advisory Council on the Misuse of Drugs (ACMD). Circular 008/2017: a Change to the Misuse of Drugs Act 1971 to Control U-47,700, Twelve Methylphenidate Related Substances and Sixteen 'designer' Benzodiazepines. Https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/616781/misuse_of_drugs_act_circular_008_2017.pdf. (Accessed Oct 6, 2019).

[98] Shapiro, A.P.; Krew, T.S.; Vazirian, M.; Jerry, J.; Sola, C. Novel Ways to Acquire Designer Benzodiazepines: A Case Report and Discussion of the Changing Role of the Internet. *Psychosomatics.*, **2019** Mar 14. pii: S0033-3182(19)30046-5. Doi: 10.1016/j.psym.2019.02.007.

[99] Robertson, M.; Raymon, L. Rohypnol VR and other benzodiazepines. In*: Drug-facilitated sexual assault: a forensic handbook.* LeBeau MA, Mozayani A (eds). London: Academic Press, **2001**:89-106.

[100] Venkatakrishnan, K.; von Moltke, L.L.; Duan, S.X.; Fleishaker, J.C.; Shader, R.I.; Greenblatt, D.J. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. *J. Pharm. Pharmacol.*, 1998, 50(3):265-74.

[101] Bird, M. Abuse potential of adinazolam: A comparison with diazepam, lorazepam and placebo. In: *Problems of Drug Dependence 1987*, Proceedings of the 49th Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph No. 81

[102] Sethy, V.H.; Collins, R.J.; Daniels, E.G. Determination of biological activity of adinazolam and its metabolites. *J Pharm Pharmacol.,* **1984,** Aug;36(8):546-8.

[103] Fraser, A.D.; Isner, A.F.; Bryan W. Urinary screening for adinazolam and its major metabolites by the Emit d.a.u. and FPIA benzodiazepine assays with confirmation by HPLC. *J Anal Toxicol*, **1993**,17 (7), 427–431.

[104] Lahti, R.A.; Sethy, V.H.; Barsuhn, C.; Hester, J.B. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. *Neuropharmacology*, **1983**, Nov;22(11), 1277-1282.

[105] File, S.E.; Pellow, S. Triazolobenzodiazepines antagonize the effects of anxiogenic drugs mediated at three different central nervous system sites. *Neurosci Lett.,* **1985,** Oct 24;61(1-2), 115-119.

[106] Venkatakrishnan, K.; Culm, K.E.; Ehrenberg, B.L.; Harmatz, J.S.; Corbett, K.E.; Fleishaker, J.C.; Greenblatt, D.J. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. *J Clin Pharmacol.*, **2005**, May;45(5), 529-37.

[107] Dunner, D.; Myers, J.; Khan, A.; Avery, D.; Ishiki, D.; Pyke, R. Adinazolam - a new antidepressant: findings of a placebo-controlled, double-blind study in outpatients with major depression. *J Clin Psychopharmacol*., **1987,** Jun;7(3), 170-2.

[108] Venkatakrishnan, K.; Von Moltke, L.L.; Duan, S.X.; Fleishaker, J.C.; Shader, R.I.; Greenblatt, D.J. Kinetic Characterization and Identification of the Enzymes Responsible for the Hepatic Biotransformation of Adinazolam and N-Desmethyladinazolam in Man. *J Pharm Pharmacol,* **1998**, 50, 265–274.

[109] Cornett, E.M.; Novitch, M.B.; Brunk, A.J.M; Davidson, K.S.; Menard, B.L.; Urman, R.D.; Kaye, A,D. New benzodiazepines for sedation. *Best Pract Res Clin Anaesthesiol.* **2018**, Jun;32(2), 149-164. Doi: 10.1016/j.bpa.2018.06.007.

[110] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2015. Annual Report on the Implementation of Council Decision 2005/387/JHA (2016). Lisbon, Portugal. Http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. (Accessed Oct 6, 2019).

[111] Dowling, G.; Kavanagh, P.V.; Eckhardt, H.G.; Twamley, B.; Hessman, G.; McLaughlin, G.; O'Brien, J.; Brandt, S.D. An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: The microscale syntheses of nitrazolam and clonazolam for use as reference materials, utilizing polymer-supported reagents. *Drug Test Anal.* **2018** Mar 15. Doi: 10.1002/dta.2383.

[112] Hester, JB. "Patent US3987052 - 6-Phenyl-4H-s-triazolo[4,3a][1,4]benzodiazepines." (**1976**). Https://patents.google.com/patent/US3987052A/en. (Accessed Oct 6, 2019).

[113] Chaslot, M.; El Balkhi, S.; Robin, T.; Morichon, J.; Picard, N.; Saint-Marcoux, F. Exploration des métabolites de 8 benzodiazépines de synthèse. *Toxicol Anal Clin*., **2016**, 28(2), S32.

[114] Høiseth, G.; Tuv, S.S.; Karinen, R. Blood concentrations of new designer benzodiazepines in forensic cases. *Forensic Sci Int.*, **2016**, 268, 35-38.

[115] Meyer, M.R.; Bergstrand, M.P.; Helander, A.; Beck, O. Identification of main human urinary metabolites of the designer nitrobenzodiazepines clonazolam, meclonazepam, and nifoxipam by nano-liquid chromatography- high-resolution mass spectrometry for drug testing purposes. *Anal Bioanal Chem.*, **2016**, 408, 3571-3591.

[116] Reddit.com. Https://www.reddit.com. (Accessed Oct 7, 2019).

[117] Kintz, P.; Richeval, C.; Jamey, C.; Ameline, A.; Allorge, D.; Gaulier, J.M.; Raul, J.S. Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism. *Drug Test Anal*., **2017,** Jul;9(7):1026-1033. Doi: 10.1002/dta.2099.

[118] Moosmann, B.; Bisel, P.; Franz, F.; Huppertz, L.M.; Auwärter, V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines - an update comprising adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam and nitrazolam. *J Mass Spectrom.* **2016** Nov;51(11),1080-1089. Doi: 10.1002/jms.3840.

[119] Mortelé, O.; Vervliet, P.; Gys, C.; Degreef, M.; Cuykx, M.; Maudens, K.; Covaci, A.; van Nuijs, A.L.N.; Lai, F.Y. In vitro Phase I and Phase II metabolism of the new designer benzodiazepine cloniprazepam using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry. *J Pharm Biomed Anal*., **2018,** May 10;153, 158-167.

[120] Schukin, S.I.; Zinkovsky, V.G.; Zhuk, O.V. Elimination kinetics of the novel prodrug cinazepam possessing psychotropic activity in mice. *Pharmacological Reports*., **2011**, Oct 31;63(5), 1093-1100.

[121] Kerrigan, S.; Mellon, M.B.; Hinners, P. Detection of phenazepam in impaired driving. *J Anal toxicol.*, **2013**, Oct 1;37(8), 605-610.

[122] Crichton, M.L.; Shenton, C.F.; Drummond, G.; Beer, L.J.; Seetohul, L.N.; Maskell, P.D. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. *Drug Test Anal.*, **2015,** Oct;7(10), 926-936. Doi: 10.1002/dta.1790.

[123] Ekonomov, A.L.; Zherdev, V.P. Method of quantitative gas-chromatographic determination of phenazepam and its metabolite 3-hydroxyphenazepam in plasma. *Pharmaceut Chem J*., **1980**, 14, 579-582.

[124] Golovenko, N.Y.; Larionov, V.B.; Kravchenko, I.A.; Ovcharenko, N.V.; Aleksandrova, A.I. Biokinetics of Transdermal 3-Hydroxyphenazepam. *Bull Exp Biol Med*. **2002** Sep 1;134(3), 254-256.

[125] Voronina, T.A.; Larionov, V.B.; Golovenko, N.; Nerobkova, L.N. [Peculiarities of hypnotic effect and pharmacokinetics of hemisuccinate 3-hydroxyphenazepam (levana)]. *Eksp Klin Farmakol.*, **2014,** 77(1), 3-6.

[126] World Health Organization (WHO)- Expert Committee on Drug Dependence (ECDD) 2015. Http://www.who.int/medicines/access/controlled-substances/5.8_Phenazepam_PreRev.pdf. (Accessed Oct 7, 2019).

[127] Lomas, E.C.; Maskell, P.D. Phenazepam: More information coming in from the cold. *J Forensic Leg Med*., **2015**, Jan 11;36, 61-62.

[128] Crichton, M.L.; Shenton, C.F.; Drummond, G.; Beer, L.J.; Seetohul, L.N.; Maskell, P.D. Analysis of phenazepam and 3-hydroxyphenazepam in post-mortem fluids and tissues. *Drug Test Analysis*., **2015**. Doi: 10.1002/dta.1790.

[129] Golovenko, N.Y.; Larionov, V.B. Pharmacodynamical and Neuroreceptor Analysis of the Permeability of the Blood-Brain Barrier for Derivatives of 1, 4-Benzodiazepine. *Neurophysiology.*, **2014**, Jun 1;46(3), 199-205.

[130] Hallifax, D.; Galetin, A.; Houston, J.B. Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines. *Xenobiotica.*, **2008**, Apr 1;38(4), 353-367.

[131] Sternbach, L.H.; Fryer, R.I.; Keller, O.; Metlesics, W.; Sach, G.; Steiger, N. Quinazolines and 1, 4-Benzodiazepines. X. 1 Nitro-Substituted 5-Phenyl-1, 4-benzodiazepine Derivatives2. *J Med Chem.*, **1963**, May;6(3), 261-265.

[132] De Silva, J.A.; Bekersky, I.; Puglisi, C.V.; Brooks, M.A.; Weinfeld, R.E. Determination of 1, 4-benzodiazepines and-diazepin-2-ones in blood by electron-capture gas-liquid chromatography. *Analytical chemistry.*, **1976,** Jan;48(1), 10-19.

[133] Maddalena, D.J.; Johnston, G.A. Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks. *J Med Chem***., 1995,** Feb;38(4), 715-724.

[134] So, S.S.; Karplus, M. Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors. *J Med chem.*, **1996**, Dec 20;39(26), 5246-5256.

[135] European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol, 2017. Annual Report on the Implementation of Council Decision 2005/387/JHA (2017). Lisbon, Portugal. Http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf. (Accessed Oct 6, 2019).

[136] Moosmann, B.; Auwärter, V. Designer Benzodiazepines: Another Class of New Psychoactive Substances. *Handb Exp Pharmacol*., **2018**;252, 383-410. Doi: 10.1007/164_2018_154.

[137] Earl, R.; Henryk, S.L., inventors; Hoffmann, La Roche, assignee. Amino substituted benzophenone oximes and derivatives thereof. United States patent US 3,136,815. **1964,** Jun 9.

[138] Skerritt, J.H.; Werz, M.A.; McLean, M.J.; MacDonald, R.L. Diazepam and its anomalous p-chloro-derivative Ro 5-4864: comparative effects on mouse neurons in cell culture. *Brain research*., **1984,** Sep 17;310(1), 99-105.

[139] Schoemaker, H.A.; Boles, R.G.; Horst, W.D.; Yamamura, H.I. Specific high-affinity binding sites for [3H] Ro 5-4864 in rat brain and kidney. *J Pharmacol Exp Therap.,* **1983**, Apr 1;225(1), 61-69.

[140] Marangos, P.J.; Patel, J.; Boulenger, J.; Clark-Rosenberg, R. Characterization of peripheral-type benzodiazepine binding sites in brain using [3H] Ro5-4864. *Mol Pharmacol*., **1982,** 22(1), 26-32.

[141] Gavioli, E.C.; Duarte, F.S.; Bressan, E.; Ferrara, P.; Farges, R.C.; De Lima, T.C. Antidepressant-like effect of Ro5-4864, a peripheral-type benzodiazepine receptor ligand, in forced swimming test. *Eur J Pharmacol.,* **2003,** Jun 13;471(1), 21-26.

[142] Dalbó, S.; Nardi, G.M.; Ferrara, P.; Ribeiro-do-Valle, R.M.; Farges, R.C. Antinociceptive effects of peripheral benzodiazepine receptors. *Pharmacology*., **2004**, Mar 4;70(4), 188-194.

[143] Leonelli, E.; Yague, J.G.; Ballabio, M.; Azcoitia, I.; Magnaghi, V.; Schumacher, M.; Garcia-Segura, L.M.; Melcangi, R.C. Ro5-4864, a synthetic ligand of peripheral benzodiazepine receptor, reduces aging-associated myelin degeneration in the sciatic nerve of male rats. *Mechanisms of ageing and development.,* **2005,** Nov 30;126(11), 1159-1163.

[144] Solhjoo, S.; O'Rourke, B. Mitochondrial instability during regional ischemia–reperfusion underlies arrhythmias in monolayers of cardiomyocytes. *J Mol Cellul Cardiol.,* **2015**, Jan 31;78, 90-99.

[145] Veiga, S., Azcoitia, I.; Garcia-Segura, L.M. Ro5-4864, a peripheral benzodiazepine receptor ligand, reduces reactive gliosis and protects hippocampal hilar neurons from kainic acid excitotoxicity. *J Neuroscience Res.,* **2005**, Apr 1;80(1):129-37.

[146] Mills, C.; Makwana, M.; Wallace, A.; Benn, S.; Schmidt, H.; Tegeder, I.; Costigan, M.; Brown, R.H.; Raivich, G.; Woolf, C.J. Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. *Eur J Neuroscience.,* **2008,** Feb 1;27(4), 937-946.

[147] Soustiel, J.F.; Zaaroor, M.; Vlodavsky, E.; Veenman, L.; Weizman, A.; Gavish, M. Neuroprotective effect of Ro5-4864 following brain injury. *Experimental neurology*., **2008**, Dec 31;214(2):201-8.

[148] Arbo, B.D.; Hoppe, J.B.; Rodrigues, K.; Garcia-Segura, L.M.; Salbego, C.G.; Ribeiro, M.F. 4'-Chlorodiazepam is neuroprotective against amyloid-beta in organotypic hippocampal cultures. *J Steroid Biochem Mol Biol.*, **2017**, Jul;171:281-287. Doi: 10.1016/j.jsbmb.2017.04.010.

[149] Ma, B.; Liu, X.; Huang, X.; Ji, Y.; Jin, T.; Ma, K. Translocator protein agonist Ro5-4864 alleviates neuropathic pain and promotes remyelination in the sciatic nerve. *Mol Pain.*, **2018**, Jan-Dec;14:1744806917748019. Doi: 10.1177/1744806917748019.

[150] Ameline, A.; Arbouche, N.; Raul, J.S.; Kintz, P. Documentation of a Little-Studied Designer Benzodiazepine After a Controlled Single Administration: II. Concentration Profile of Deschloroetizolam in Saliva. *Ther Drug Monit.*, **2018**, Dec;40(6):759-761. Doi: 10.1097/FTD.0000000000000557.

[151] Moosmann, B.; Bisel, P.; Westphal, F.; Wilde, M.; Kempf, J.; Angerer, V.; Auwärter, V. Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864). *Drug Test Anal.*, **2019,** Mar;11(3): 541-549. Doi: 10.1002/dta.2561.

[152] Manchester, K.R.; Lomas, E.C.; Waters, L.; Dempsey, F.C.; Maskell, P.D. The emergence of new psychoactive substance (NPS) benzodiazepines: A review. *Drug Test Anal.*, **2017**, 1–17. Doi:10.1002/dta.2211.

[153] Hester, J.B. Jr.; Von Voigtlander, P. 6-Aryl-4H-s-triazolo[4, 3-a][1,4] benzodiazepines. Influence of 1-substitution on pharmacological activity. *J. Med. Chem.*, **1979**, 22(11), 1390-1398.

[154] Vogt, S.; Kempf, J.; Buttler, J.; Auwärter, V.; Weinmann, W. Desalkylflurazepam found in patients' samples after high-dose midazolam treatment. *Drug testing and analysis*, **2013**, Sep 1;5(9-10), 745-747.

[155] Maskell, P.D.; Wilson, N.E. Designer Benzodiazepines: New Challenges and Treatment Options, in Corazza O, Roman-Urrestarazu. In: *Handbook of Novel Psychoactive Substances: What Clinicians Should Know about NPS*. Taylor & Francis, 2019. ISBN 978-1-138-06830-8.

[156] Akatsu M. Benzodiazepine derivatives. *Jpn. Kokai Tokkyo Koho*, 1**972**, JP 47030683 B 19721109.

[157] Winkler, A.D.; Burden, F.R.; Watkins, A.J.R. "Atomistic Topological Indices Applied to Benzodiazepines using Various Regression Methods". *Quantitative Structure-Activity Relationships*, **1998**, 17 (1): 14–19. Doi:10.1002/(SICI)1521-3838(199801)17:013.0.CO;2-U.

[158] Reeder, E., inventor. Process for preparing 5-phenyl-1,2-dihydro-3H-1,4-benzodiazepines. United States patent US 3,109,843. **1963**, Nov 5.

[159] Anjaneyulu, Y.; Marayya, D.; Linga, R.D.; Krishna, R.P. High performance thin layer chromatographic determination of the related substances in alprazolam drug. *Asian J Chemistry*., **2007,** Jul 1;19(5), 3375.

[160] Baumann, M.; Baxendale, I.R.; Ley, SV; Nikbin, N. An overview of the key routes to the best-selling 5-membered ring heterocyclic pharmaceuticals. *Beilstein J Org Chem.*, **2011**, 7, 442-495.

[161] Borrey, D.; Meyer, E.; Lambert, W.; Van Calenbergh, S.; Van Peteghem, C.; De Leenheer AP. Sensitive gas chromatographic-mass spectrometric screening of acetylated benzodiazepines. *J Chromatogr A.*, **2001**; 910: 105-118.

[162] Wilhelm, M.; Battista, H.J.; Obendorf, D. HPLC with simultaneous UV and reductive electrochemical detection at the hanging mercury drop electrode: a highly sensitive and selective tool for the determination of benzodiazepines in forensic samples. *J Anal Toxicol.*, **2001**, 25(4): 250-257.

[163] Bugey, A.; Rudaz, S.; Staub, C. A fast LC-APCI/MS method for analyzing benzodiazepines in whole blood using monolithic support. *J Chromatogr B. Analyt Technol Biomed Life Sci.*, **2006**, 832, 249-255.

[164] Ueki, S.; Gomita, Y.; Ataki, Y.; Yamada, K.; Yoshimura, H. Behavioral effects of 5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one (ID-690). *Nippon Yakurigaku Zasshi.*, **1977**, 73(2), 243-255.

[165] Fukuda, H.; Kudo, Y.; Ono, H.; Togari, A.; Tanaka, Y. Pharmacological study on 5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one (ID-690), with special reference to the effects on motor systems. *Nippon Yakurigaku Zasshi.*, **1977**, 73(1), 123-134.

[166] Fukuda, H.; Kudo, Y.; Takeuchi, E. Effects of benzodiazepine derivatives on γ-motor system in rats. *Nippon Yakurigaku Zasshi.*, **1979,** 75(4), 315-319].

[167] Watanabe, S.; Kawasaki, H.; Nishi, H.; Ueki, S. Electroencephalographic effects of ID-690 [5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one] in rabbits with chronic electrode implants. *Nippon Yakurigaku Zasshi*., **1974**, 70(4), 531-542

[168] Tsuchiya, T.; Fukushima, H. Effects of 5-(o-chlorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one (ID-690) as compared to nitrazepam on the sleep-wakefulness cycle in cats. *Nippon Yakurigaku Zasshi.*, **1977,** 73(4), 437-447.

[169] Hellerbach, J. Thienotriazolodiazepine. **1974**. DE 2405682. Hoffmann-La Roche Inc. Https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=DE&NR=2405682A1&KC=A1&FT=D&ND=3&date=19740815&DB=EPODOC&locale=en_EP#. (Accessed Oct 7, 2019).

[170] Zawilska, J.B.; Wojcieszak, J. An expanding world of new psychoactive substances-designer benzodiazepines. *Neurotoxicology.*, **2019,** Jul;73, 8-16. Doi:10.1016/j.neuro.2019.02.015.

[171] ukchemicalresearch.org. Https://www.ukchemicalresearch.org. (Accessed Oct 7, 2019).

[172] Zsila, F.; Gergely, A.; Horvath, P.; Szasz, G. Separation and identification of tofisopam stereoisomers by hyphenated HPLC-CD technique. *J Liq Chrom Relat Tech***., 1999,** 22(5), 713-719.

[173] Foroughbakhshfasaei, M.; Szabó, Z.I.; Mirzahosseini, A.; Horváth, P.; Tóth, G. Enantiomeric quality control of R-Tofisopam by HPLC using polysaccharide-type chiral stationary phases in polar organic mode. *Electrophoresis.,* **2018,** Oct;39(20), 2566-2574. Doi: 10.1002/elps.201800220.

[174] Bond, A.; Lader, M. A comparison of the psychotropic profiles of tofisopam and diazepam. *Eur J Clin Pharmacol.*, **1982;** 22(2), 137-142.

[175] Bernard, P.; Dufresne-Favetta, C.; Favetta, P.; Do, Q.T.; Himbert, F.; Zubrzycki, S.; Scior, T.; Lugnier, C. Application of drug repositioning strategy to TOFISOPAM. *Curr Med Chem.*, **2008**, 15(30), 3196-3203.

[176] Murthy, V.S.; Mangot, A.G. Psychiatric aspects of phosphodiesterases: An overview. *Indian J Pharmacol***., 2015**, Nov-Dec;47(6), 594-599. Doi: 10.4103/0253-7613.169593.

[177] Tominaga, K.; Fujikawa, Y.; Tsumoto, C.; Kadouchi, K.; Tanaka, F.; Kamata, N.; Yamagami, H.; Tanigawa, T.; Watanabe, T.; Fujiwara, Y.; Arakawa, T. Disorder of autonomic nervous system and its vulnerability to external stimulation in functional dyspepsia. *J Clin Biochem Nutr*., **2016,** Mar;58(2), 161-165. Doi: 10.3164/jcbn.15-140.

[178] Pellow, S; File, S.E. Is tofisopam an atypical anxiolytic? *Neurosci Biobehav Rev*., **1986**, Summer;10(2), 221-227.

[179] Petocz, L. Pharmacologic effects of tofizopam (Grandaxin). *Acta Pharm. Hung*., **1993**, 63, 79-82.

[180] Srivastava, S; Bhatia, M.S.; Gupta, K.; Rajdev, K. Current update on evidence based literature of tofisopam. *Delhi Psychiatry J.*, **201**4, 17, 154–159.

[181] Chopin, P.; Stenger, A., Couzinier, J.P.; Briley, M. Indirect dopaminergic effects of tofisopam, a 2,3-benzodiazepine, and their inhibition by lithium. *J Pharm Pharmacol*., **1985**, Dec;37(12), 917-919.

[182] Szegó, J.; Somogyi, M.; Papp, E. Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin]. *Acta Pharm Hung.*, **1993,** Mar; 63(2), 91-8.

[183] Rundfeldt C.; Socała, K.; Wlaź, P. The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. *J Neural Transm (Vienna)*, **2010** Nov; 117(11), 1319-1325.

[184] Bihel, F.J.; Justiniano, H.; Schmitt, M.; Hellal, M.; Ibrahim, M.A.; Lugnier, C.; Bourguignon, J.J. New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam. Bioorg Med Chem Lett. **2011** Nov 1;21(21), 6567-6572. Doi: 10.1016/j.bmcl.2011.08.036.

[185] Vakhrushev, I.M.; Belova, E.V.; Efremova, L.I. [Use of grandaxine in the treatment of patients with erosive-ulcerative stomach and gastroduodenal lesions]. *Eksp Klin Gastroenterol*., **2004,** (4), 21-24.

[186] Plotnikova, E.; Beloborodova, E.I. [Use of grandaxin in hypermotor dysfunction of the biliary ducts in young people]. *Eksp Klin Gastroenterol*., **2005**;(6):65-70, 113-114.

[187] Leventer, S.M.; Raudibaugh, K.; Frissora, C.L.; Kassem, N.; Keogh, J.C.; Phillips, J.; Mangel, A.W. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. *Aliment Pharmacol Ther.*, **2008,** Jan 15;27(2), 197-206.

[188] Manabe, N.; Rao, A.S.; Wong, B.S.; Camilleri, M. Emerging pharmacologic therapies for irritable bowel syndrome. *Curr Gastroenterol Rep*., **2010** Oct;12(5), 408-416. Doi:10.1007/s11894-010-0124-1.

[189] Klebovich, I.; Abermann, M. Pharmacokinetics and metabolism of tofizopam (Grandaxin). *Acta Pharm Hung*., **199**3; 63(2), 83-90.

[190] Tomori, E.; Elekes, I.;, Láng, T.; Horváth, G. Investigation of metabolites of tofizopam in man and animals. *Pol J Pharmacol Pharm.*, **1984**, 36(4), 423-430.

[191] Hatayama, M.; Sumida, C.; Kurajoh, M.; Shiraishi, J.; Okazaki, H.; Shoji, T.; Koyama, H.; Tsutsumi, Z.; Moriwaki, Y.; Namba, M.; Yamamoto, T. Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol "Preliminary Communication". *Curr Clin Pharmacol*., **2015,** 10(2), 160-164. Doi: 10.2174/1574884710666150126143421.

[192] Veĭn, A.V.; Artemenko, A.R.; Oknin, V.I.; Pomortseva, I.V. [Effectiveness of grandaxin in the treatment of somatoform disorders]. *Klin Med (Mosk).*, **1999**, 77(6), 41-45.

[193] Osipenko, M.F.; Khramov, I.A.; Makarova, T.A.; Vdovenko, E.G. [Role of grandaxin in the treatment of functional gastrointestinal diseases]. *Ter Arkh*., **2000,** 72(10), 23-27.

[194] Kato, R.; Ooi, K.; Ueno, K. [A case in which tofisopam was effective for treatment of paroxysmal supraventricular tachycardia]. *Yakugaku Zasshi.*, **2003**, May;123(5), 365-368.

[195] Fustero, S.; González, J.; Del Pozo, C. 1, 4-Benzodiazepine N-nitrosoamidines: useful intermediates in the synthesis of tricyclic benzodiazepines. *Molecules.*, **2006,** 11(8), 583-588.

[196] Kaliszan, R.; Kaliszan, A.; Noctor, T.A.; Purcell, W.P.; Wainer, I,W. Mechanism of retention of benzodiazepines in affinity, reversed-phase and adsorption high-performance liquid chromatography in view of quantitative structure retention relationships. *Journal of Chromatography A.* **1992**, 609(1-2), 69-81.

[197] Garzone, P.D.; Kroboth, P.D. Pharmacokinetics of the newer benzodiazepines. *Clinical pharmacokinetics*., **1989,** 16(6), 337-364.

[198] Qian, Z.,; Liu, C.,; Huang, J.,; Deng, Q.,; Hua, Z. Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case. *Forensic Toxicology*, **2019,** https://doi.org/10.1007/s11419-019-00501-1.

[199] Drug-café. https://drug.cafe/. (Accessed Oct 8, 2019).

[200] RCshare. Https://rceshare.blogspot.com. (Accessed Oct 8, 2019).

[201] Vejdelek, Z.; Protiva M. Synthesis of two 1-substituted 8-bromo-6-(2-chlorophenyl)-4H-s-triazolo[4,3-a]-1,4-benzodiazepines. *Collect. Czech. Chem. Comm.* **198**3; 48(5), 1477-1482.

[202] Gonzalez López, F.; Mariño, E.L.; Dominguez-Gil, A. Pharmacokinetics of tiadipone: a new anxiolytic. *Int J Clin Pharmacol Ther Toxicol*., **1986,** 24(9), 482–484.

[203] CIMA. Medicine Online Information Center of AEMPS (from the Spanish: Centro de Información Online de Medicamentos de la Agencia española de medicamentos y productos sanitarios). Https://hes32-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fcima.aemps.es%2fcima%2fpublico%2fhome.html&umid=7cec72cc-7e38-4174-a2ab-f34a2ce0e3fe&auth=768f192bba830b801fed4f40fb360f4d1374fa7c-400a686fb11df4fef2d673976f3bd27783f37b2d (Accessed Oct 8, 2019).

[204] Tiadipona ® Summary of Product Characteristics (in Spanish). Https://hes32-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fcima.aemps.es%2fcima%2fpdfs%2fes%2fft%2f55464%2fFT%5f55464.html.pdf&umid=7cec72cc-7e38-4174-a2ab-f34a2ce0e3fe&auth=768f192bba830b801fed4f40fb360f4d1374fa7c-a12cdbf593fc8f257f0923c787e8e41839adbeb2. (Accessed Oct 8, 2019).

[205] Andrade, R.J.; Lucena, M.I.; Alcantara, R.; Fraile, J.M. Bentazepam-associated chronic liver disease. *Lancet.* **1994**, 343(8901), 860.

[206] de-la-Serna, C.; Gil-Grande, L.A.; Sanromán, A.L.; Gonzalez, M.; Ruiz-del-Arbol, L.; Garcia Plaza, A. Bentazepam-induced hepatic bridging necrosis. *J Clin Gastroenterol*., **1997,** Dec;25(4), 710-711.

[207] Andrade, R.J.; Lucena, M,I,; Aguilar, J.; Lazo, M.D.; Camargo, R.; Moreno, P.; García-Escaño, M.D.; Marquez, A.; Alcántara, R.; Alcáin, G. Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. *Dig Dis Sci.*, **2000,** 45(7), 1400–1404.

[208] Andrade, R.J.; López-Torres, E.; Lucena, M.I.; Fernández, M. Acute hepatitis due to bentazepam. *Med Clin (Barc).*, **2003**, 120(17), 678–679.

[209] Andrade R.J.; Lucena, M.I.; Kaplowitz, N.; García-Muņoz, B.; Borraz, Y.; Pachkoria, K.; García-Cortés, M.; Fernández, M.C.; Pelaez, G.; Rodrigo, L.; Durán, J.A.; Costa, J.; Planas, R.; Barriocanal, A.; Guarner, C.; Romero-Gomez, M.; Muņoz-Yagüe, T.; Salmerón, J.; Hidalgo, R. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. *Hepatology.*, **2006,** Dec;44(6), 1581-1588.

[210] Baumeister, D.; Tojo, L.M.; Tracy, D.K. Legal highs: staying on top of the flood of novel psychoactive substances. *Ther Adv Psychopharmacol.*, **2015**, Apr;5(2), 97-132. Doi: 10.1177/2045125314559539.

[211] Schifano, F.; Orsolini, L.; Papanti, D.G.; Corkery, J.M. Novel psychoactive substances of interest for psychiatry. *World Psychiatry*., **2015**, Feb;14(1), 15-26. Doi: 10.1002/wps.20174.

[212] Pope, J.D.; Choy, K.W.; Drummer, O.H.; Schneider, H.G. Novel benzodiazepines (clonazolam and flubromazolam) identified in candy-like pills. *J. Appl. Lab. Med., 2018,* 3 (1), 48–55. Doi:10.1373/jalm.2017.025387.

[213] Griffin, C.E.; Kaye, A.M.; Bueno, F.R.; Kaye, A.D. Benzodiazepine pharmacology and central nervous system-mediated effects. *The Ochsner J.*, **2013**, 13(2), 214-223.

[214] Broséus, J.; Gentile, N.; Esseiva, P. The Cutting of Cocaine and Heroin: A Critical Review. *For Sci Intern,* **2016**, 262, 73-83.

[215] El Balkhi, S.; Chaslot, M.; Picard, N.; Dulaurent, S.; Delage, M.; Mathieu, O.; Saint-Marcoux, F. Characterization and identification of eight designer benzodiazepine metabolites by incubation with human liver microsomes and analysis by a triple quadrupole mass spectrometer. *Int J Legal Med*., **2017**, Jul;131(4), 979-988. Doi: 10.1007/s00414-017-1541-6.

[216] Orsolini, L.; Papanti, G.D.; Francesconi, G.; Schifano, F. Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts. *Cyberpsychol Behav Soc Netw.*, **2015**, May;18(5), 296-300. Doi: 10.1089/cyber.2014.0486.

[217] Corkery, J.M.; Orsolini, L.; Papanti, D.; Schifano, F. From concept(ion) to life after death/the grave: The 'natural' history and life cycle(s) of novel psychoactive substances (NPS). *Hum Psychopharmacol*., **2017,** May;32(3). Doi: 10.1002/hup.2566. Review.

[218] Orsolini, L.; Papanti, D.; Corkery, J.; Schifano, F. An insight into the deep web; why it matters for addiction psychiatry? *Hum Psychopharmacol*., **2017**, May;32(3). Doi: 10.1002/hup.2573. Review.

[219] Vinkers, C.H.; Tijdink, J.K.; Luykx, J.J.; Vis, R. Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics. *Ned Tijdschr Geneeskd*., **2012,** 155(35), A4900.

[220] Turner, S.; Mota, N.; Bolton, J.; Sareen, J. Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. *Depress Anxiety*., **2018**, 35(9), 851-860. doi: 10.1002/da.22771.

[221] Jones, J.D.; Jones, S.; Mogali, S.D. Comer, Polydrug abuse: a review of opioid andbenzodiazepine combination use, *Drug Alcohol Depend*., **2012,** 125, 8–18.

Table 2. List of current new/designer Benzodiazepines

Name of BZD (CAS registry number)	Chemical formula (molecular weight, g/mol)	Molecular Structure	Systematical Chemical Name (IUPAC name) Other or street names	Year patented (Year notified to the EMCDDA)	Aspect and characteristics	User reports of effects (typical recreational dose, mg)
Phenazepam (51753-57-2)	$C_{15}H_{10}BrClN_2O$ (349.6)		(7-bromo-5-(2-chlorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) *Other/Street Names*: Fenazepam; BD 98; Elzepam; Phezipam; Phenorelaxan; Phenzitat; Bonzai; Bonsai; Supersleep; Fenaz; Soviet Benzo; Zannie	1974 (2007, UK)	White crystalline powder with a greyish-yellow tinge, odorless and tasteless, insoluble in water and soluble in ethanol, dimethylformamide and chloroform	Anxiolytic, extremely sedating, sort-term memory loss, blackouts at higher doses, insomnia, delirium, psychotic episodes (0.5-1)
Etizolam (40054-69-1)	$C_{17}H_{15}ClN_4S$ (342.1)		4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine *Other/Street Names*: AHR 3219; Depas; Y-7131; Etizola; Sedekopan; Pasaden; Etizest; Etilaam; Etiz; Etizzy	1978 (2011, UK)	White crystalline powder Tablets Blotters similar to LSD paper doses	Anxiolytic, muscle relaxation, sleep-aid, euphoria (0.25-3)

Pyrazolam (39243-02-2)	$C_{16}H_{12}BrN_5$ (354.2)		8-bromo-1-methyl-6-(pyridin-2-yl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: 1-methyl[1,2,4]triazo-6-(2-pyridinyl)-8-bromo-1,4-benzodiazepine	1979 (2011, Finland)	Tablets	Effects lasting 6-7 hours, anxiolytic, low sedation, low hypnotic effect, low recreational value (1)
Flubromazepam (2647-50-9)	$C_{15}H_{10}BrFN_2O$ (331.1)		7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one *Other/Street Names*: NA	1962 (2013, Germany)	Capsules	Effects lasting 18-24 hours, anxiolytic, mild euphoria, blackouts, sedating and muscle relaxation, short-term memory loss (4)

Diclazepam (2894-68-0)	$C_{16}H_{12}Cl_2N_2O$ (319.2)		7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one *Other/Street Names*: Ro 5-3448; 2-chlorodiazepam; chlorodiazepam	1964 (2013, Sweden)	Blue tablets	Effects lasting 5-12 hours, anxiolytic, useful for 'tapering' dependence of other BZDs, low cognitive impairment, low recreational value (1-2)
Alprazolam triazolobenzophenone derivative (125316-83-8)	$C_{17}H_{15}ClN_4O$ (326.8)		[2-[3-(Aminomethyl)-5-methyl-4H-1,2,4-triazol-4-yl]-5-chlorophenyl] phenylmethanone *Other/Street Names*: NA	1986 (2014, Spain)	White powder	Anxiolytic (NA)

Meclonazepam (S-enantiomer: 58662-84-3; Racemate: 67027-56-9)	$C_{16}H_{12}ClN_3O_3$ (329.7)		(S)-5-(2-chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one *Other/Street Names*: (S)-3-methylclonazepam; Ro 11-3128; Ro 11-3624; Meclonazepamum; Methylclonazepam; 3-methylclonazepam	1975 (2014, Sweden)	White powder	Low sedation, anxiolytic, muscle relaxation (2-3)
Deschloroetizolam (40054-73-7)	$C_{17}H_{16}N_4S$ (308.4)		2-ethyl-9-methyl-4-phenyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin *Other/Street Names*: ETZ-2; etizolam-2	1998 (2014, UK)	Blue tablets	Effects lasting 12-24 hours, anxiolytic, sedation, slight euphoria (4-6)

Flubromazolam (612526-40-6)	$C_{17}H_{12}BrFN_4$ (371.2)		8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: JYI-73	1978 (2014, Sweden)	White rectangle shaped tablets	Effects lasting 12 – 18 hours, anxiolytic, high tolerance to lower doses quickly observed, blackouts and memory loss, strongly sedating, higher doses of 2.5 – 4 mg have effects reported to last up to 3 days and strong memory loss and cognitive impairment. Ingestion of 3 mg of flubromazolam 19 hours prior to hospitalization has been reported in a patient. Severe respiratory failure, hypotension, central nervous system depression and brain damage were observed. (0.15-0.25)

Nifoxipam (74723-10-7)	$C_{15}H_{10}FN_3O_4$ (315.3)		5-(2-fluorophenyl)-3-hydroxy-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one *Other/Street Names*: 5-(2-fluorophenyl)-3-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 3-hydroxydesmethylflunitrazepam; DP-370	1985 (2015, Sweden)	Brown tablets	Effects lasting 12 – 18 hours, anxiolytic, moderately sedating, mild euphoric, High doses can cause users to feel sleep-deprived, muscle relaxant (0.5-2)
Clonazolam (33887-02-4)	$C_{17}H_{12}ClN_5O_2$ (353.8)		6-(2-chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: clonitrazolam	1971 (2014, Sweden)	White powder in yellow tablets	Slight euphoria, strongly sedating (0.5-1)

Adinazolam (37115-32-5)	$C_{19}H_{18}ClN_5$ (351.8)		1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,5-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine *Other/Street Names*: Deracyn®; Adinazolamum; 8-chloro-1-[(dimethylamino) methyl]-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine	1976 (2015, Germany, Sweden and Slovenia)	White powder White tablet labelled "D/CD"	Strongly sedating, anterograde amnesia (20)
Nitrazolam (28910-99-8)	$C_{17}H_{13}N_5O_2$ (319.3)		1-methyl-8-nitro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: NA	1971 (2015, Germany)	Light brown powder	Anxiolytic, hypnotic, strongly sedating (0.5-2)

Metizolam (40054-68-0)	$C_{16}H_{13}ClN_4S$ (328.8)		4-(2-chloro-phenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine *Other/Street Names*: desmethyletizolam	1988 (2015, Germany and Denmark)	Light-blue or blue round tablets	Anxiolytic and muscle relaxation, effects not as strong as etizolam (2)
Cloniprazepam (1998158-84-1)	$C_{19}H_{16}ClN_3O_3$ (369.8)		5-(2-Chlorophenyl)-1-(cyclopropylmethyl)-7-nitro-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one *Other/Street Names*: 7-nitro-1-(cyclo-propyl(methyl))-1,3-dihydro-5-(2-chlorophenyl)-2H-1,4-benzodiazepin-2-one; kloniprazepam; 2-chloro-7'-nitroprazepam; 1-cyclopropylmethylclonazepam	Not reported (2015, Sweden)	White capsule	Slight anxiolytic, higher doses (>5-10 mg) required for muscle relaxation, sedation in most users (2.5)

3-hydroxyphenazepam (70030-11-4)	$C_{15}H_{10}BrClN_2O_2$ (365.6)		7-bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one *Other/Street Names*: 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 3-HOP; HPNZ; 3-oxyfenazepam; 3-hydroxyfenazepam	Not reported (2016, Sweden)	White tablet and pale blue tablet	Anxiolytic, slight muscle relaxation, strongly sedating (0.5-2)
Fonazepam (2558-30-7)	$C_{15}H_{10}FN_3O_3$ (299.3)		5-(2-fluorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one *Other/Street Names*: Desmethyl-flunitrazepam; Norflunitrazepam; Ro 05-4435; N-desmethylflunitrazepam	1963 (2016, Sweden)	white, blue and grey tablets white/yellow powder	Anxiolytic, muscle relation, sedation (0.6)
4-chlorodiazepam (14439-61-3)	$C_{16}H_{12}ClN_2O$ (319.2)		7-chloro-5-(4-chlorophenyl)-1-methyl-3*H*-1,4-benzodiazepin-2-one *Other/Street Names*: 7-chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one; 7-chloro-1,3-dihydro-1-methyl-5-(p-chlorophenyl)-2*H*-1,4-benzodiazepine-2-one; 4-chlorodiazepam; 4'-chlorodiazepam; Ro 5-4864; Ro5-4864; Chlorodiazepam	1964 (2016, Slovenia)	Off-white powder	Pro-convulsing effects, also at lower doses neuroprotective, sedative (NA)

Flunitrazolam (2243815-18-9)	$C_{17}H_{12}FN_5O_2$ (337.1)		6-(2-fluorophenyl) -1-methyl-8-nitro-4H-[1,2,4] triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: Fluclazolam	1960 (2016, Germany)	White Powder Grey and blue Tablets Pellets and soaked into paper strips	Strong sedative, slight amnesia reported, anxiolytic (0.8-1.5)
Bromazolam (71368-80-4)	$C_{17}H_{13}BrN_4$ (353.2)		8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, 8-bromo-1-methyl-6-phenyl-;8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine; XLI-268	1976 (2016, Sweden)	Yellow powder	No published reports (1-3)

Norfludiazepam (2886-65-9)	$C_{15}H_{10}ClFN_2O$ (288.7)		7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one *Other/Street Names*: Chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-[1,4]-benzodiazepin-2-one, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one; N-desalkylflurazepam; Desalkylflurazepam; Norflurazepam; Desalkylflurazepam; Norflutoprazepam; Ro 5-3367	1962 (2016, Sweden and Germany)	Orange tablet White powder	Strongly sedating and long lasting effects (5)
Ro 07-4065 (39080-67-6)	$C_{16}H_{11}ClF_2N_2O$ (320.7)		7-chloro-5-(2,6-difluorophenyl)-1-methyl-3H-1,4-benzodiazepin-2-one *Other/Street Names*: 7-chloro-5-(2,6-difluorophenyl)-1-methyl-1,3-dihydro-2H-benzo[e][1,4]diazepin-2-one, 7-chloro-5-(2,6-difluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one, 7-chloro-5-(2,6-difluorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; Ro-07-4065; Difludiazepam	1972 (2017, Sweden)	Pale beige powder	No published reports (NA)

Thionordiazepam (4547-02-8)	$C_{15}H_{11}ClN_2S$ (286.8)		7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione *Other/Street Names*: 7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepine-2-thione7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-thione; 7-chloro-5-phenyl-1,3-dihydro-1,4-benzodiazepine-2-thione, 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-thione; Thionordiazepam; Thionordiaze-pam	1963 (2017, Sweden)	Pale yellow powder	No published reports (NA)
Methyl-clonazepam (5527-71-9)	$C_{16}H_{12}ClN_3O_3$ (329.7)		5-(2-chlorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one *Other/Street Names*: 5-(2-chlorophenyl)-1,3-dihydro-1-methyl-7-nitro-2H-1,4-benzodiazepin-2-one5-(2-chlorophenyl)-1-methyl-7-nitro-(1,4)-benzodiazepin-2-one5-(o-chlorophenyl)-1-methyl-7-nitro-(1,4)-benzodiazepin-2-one5-(2-chlorophenyl)-1,3-dihydro-7-nitro-1,4-benzodiazepin-2-one; ID 690; ID-690; Ro 05-4082; R 5-4082	1974 (2017, Sweden)	Pale yellow powder	Anxiolytic effect more potent than lorazepam (1-6)

Fluclotizolam (54123-15-8)	$C_{15}H_{10}ClFN_4S$ (332.8)		2-chloro-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine *Other/Street Names*: 4-(2-fluorophenyl)-2-chloro-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	1974 (2017, Sweden and Denmark)	Pale green tablets Blotters	Potent hypnotic (0.25-0.5)
Tofisopam (22345-47-7)	$C_{22}H_{26}N_2O_4$ (382.5)		1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine *Other/Street Names*: 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 7,8-dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Grandaxin®; Emandaxin®; EGYT 341; Nodeprine; Sériel; TF	1978 (2017, Sweden)	White tablet labelled 'GRANDAX' in blister packs	Anxiolytic effects with increased concentration, memory and attention, no withdrawal effects (NA)

Flualprazolam (28910-91-0)	$C_{17}H_{12}ClFN_4$ (326.8)		8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloro-6-(2-fluorophenyl)-1-methyl-4*H*-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine; 12-chloro-9-(2-fluorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2},^{6}]tetradeca-1(14),3,5,8,10,12-hexaene; Ro 11-5073/000	1971 (2017, Sweden)	Pale beige and yellow powder Tablet Pellet	No published reports (NA)
Clobromazolam (87213-50-1)	$C_{17}H_{12}BrClN_4$ (387.7)		8-bromo-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine *Other/Street Names*: 8-bromo-6-(2-chlorophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; Phenazolam; BRN 4550445; DM-II-90	1983 (2016, Sweden)	White capsule containing white powder	No published reports (NA)

Bentazepam (Free base: 29462-18-8; Hydrochloride salt: 29462-19-9)	$C_{17}H_{16}N_2OS$ (296.3)		5-phenyl-1,3,6,7,8,9-hexahydro-2H-[1]benzothieno[2,3-e][1,4]diazepin-2-one *Other/Street Names*: 5-phenyl-1,3,6,7,8,9-hexahydrobenzothiopheno[2,3-e][1,4]diazepin-2-one; CI 718; QM 6008; Thiadipone; Tiadipone; 608-362-7 (EC No); 29349990 (EU Customs Code CN)	1986 (2014, Sweden)	White round tablets	Limited published reports (30-50)

(Chemical structures performed by using ChemDraw for professionals version 16.0)

Table 1. Pharmacokinetic and chemical structure classification of traditional and some new/designer BZDs

SHORT / ULTRA-SHORT PLASMA HALF-LIFE (t½) BZD - I GROUP
• ***Drug name (traditional)***: *a) Triazolobenzodiazepines*: e.g., Alprazolam; Estazolam; Triazolam *b) Thienobenzodiazepines:* e.g., Bentazepam; Brotizolam; Clotiazepam • ***NPS***: *a) Triazolobenzodiazepines*: Adinazolam; Alprazolam triazolobenzophenone derivative; Bromazolam; Clobromazolam; Clonazolam (clonitrazolam); Flualprazolam; Flubromazolam; Flunitrazolam; Nitrazolam; Pyrazolam; Thionordazepam; Zapizolam *b) Thienobenzodiazepines:* thienotriazolodiazepines (Etizolam; Deschloroetizolam; Metizolam; Fluclotizolam)
• ***Pharmacokinetic features*** *a) Plasma half-life*: increased in elderly patients and in those with liver disease. *a) Triazolobenzodiazepines*: 6-24 hours. *b) Thienobenzodiazepines:* 2-6 hours. *b) Metabolism*: hydroxylation and conjugation with glucuronic acid.
• ***Accumulation***: after prolonged use.
• ***Interactions***: Cimetidine, propranolol, fluoxetine, paroxetine, fluvoxamine and oral contraceptives inhibit the processes of hepatic hydroxylation (P-450), and decrease the metabolism of these BZD, increasing their plasma levels. Excessive sedative effects and hypotension when combined with alcohol.
SHORT / ULTRASHORT PLASMA HALF-LIFE (t½) BZD - II GROUP
• ***Drug name (traditional)***: *Oxazepam-like BZD*: Camazepam; Lorazepam; Lormetazepam; Oxazepam; Temazepam. • ***NPS***: Flutazolam; Nimetazepam (belonging to 1,4-BZD family)
c) ***Pharmacokinetic features:*** no modification in elderly patients or in those with liver disease. *a) Plasma half-life*: 10-24 hours. *b) Metabolism*: conjugation with glucuronic acid. No active metabolites.
• ***Accumulation***: no accumulation.
• ***Interactions***: No relevant pharmacokinetic interactions. Excessive sedative effect and risk of hypotension when combined with alcohol or CNS sedative drugs.

MEDIUM / LONG PLASMA HALF-LIFE (t½) BZD
• ***Drug name (traditional)***
a) Pronordiazepam-like BZD: Bromazepam; Chlorazepate; Chlordesmetildiazepam; Chlordiazepoxide; Clobazam; Desmethyldiazepam; Diazepam; Flurazepam; Ketazolam; Medazepam; Pinazepam; Prazepam; Quazepam.
b) *Nitro-BZD:* Clonazepam; Flunitrazepam; Nitrazepam.
• ***NPS:***
a) *Pronordiazepam-like BZD:* 4'-chlorodiazepam or Ro 5-4864 (belonging to 1,4-BZD family); Diclazepam or Ro 5-3448 (belonging to 1,4-BZD family); Flubromazepam (belonging to 1,4-BZD family); Meclonazepam (belonging to 1,4-BZD family); Norfludiazepam or Ro 5-3367 (belonging to 1,4-BZD family); Ro 07-4065 (belonging to 1,4-BZD family).
b) *Nitro-BDZ:* 3-hydroxyphenazepam (belonging to 1,4-BZD family); Cloniprazepam (belonging to 1,4-BZD family); Fonazepam or Ro-4435 (belonging to 1,4-BZD family); Methylclonazepam (belonging to 1,4-BZD family); Nifoxipam or DP 370 (belonging to 1,4-BZD family); Phenazepam (belonging to 1,4-BZD family).
• ***Pharmacokinetic features***
a) Plasma half-life: 24-48 hours (nitro-BZD); >48 hours (pro-nordiazepam-like BZD). Plasma t½ increases in elderly and patients with liver diseases.
b) Metabolism: demethylation to nordiazepam, hydroxylation and conjugation by glucuronic acid; nitro-reduction and conjugation by glucuronic acid. Active metabolites with long plasma half-life.
• ***Accumulation***: after long-term treatment.
• ***Interactions:*** cimetidine, propranolol, fluoxetine, paroxetine, fluvoxamine, and oral contraceptives, decrease hepatic hydroxylation (CYP-450) and increase plasma levels of these BZD. Combination with alcohol and CNS depressant drugs induces severe sedative and hypotensive effects.